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1.1 Cystic Fibrosis  
1.1.1 Pathophysiology of the disease  
Cystic Fibrosis (CF) is a lethal, inherited and autosomal recessive disorder that affects approximately 1 
every 3000 births [1]. 
CF is caused by mutations in the gene encoding for the cystic fibrosis transmembrane conductance 
regulator (CFTR) protein, a transmembrane anion channel situated at the apical membrane of epithelial 
cells of the airway, the gastrointestinal tract, the pancreas, and the biliary and sweat ducts. CFTR regulates 
the transport of chloride and bicarbonate ions in and out of the cells. This protein has an important role 
in the regulation of epithelial ion and water transport and fluid homeostasis. 
The first comprehensive description of CF was given in 1938 by Dr. Dorothy H. Andersen [2], a pathologist 
at the New York Babies Hospital, who introduced the term “Cystic Fibrosis of the pancreas” to describe 
the destruction of the pancreatic exocrine function as a result of the disease. Another major advance in 
the history of CF research was achieved by Dr. Paul Di Sant’Agnese in 1953, who demonstrated that the 
sweat of CF children had an excessive salt content [3]. His findings led to the first method for CF diagnosis, 
the sweat test, which measures the concentration of sodium and chloride in the sweat. In the  1980s, Dr. 
Paul M. Quinton defined the salt transport abnormality and demonstrated the attenuated chloride 
transport in sweat ducts [4], [5]. A similar abnormality in the respiratory epithelium was also described by 
Dr. Michael Knowles [6] in 1983.     
The CFTR gene, located on the long arm of chromosome 7 at position q31.2 [7], was identified and cloned 
in 1989 [8]. Since its discovery, both the CFTR structure and function have been deeply investigated. These 
efforts improved our understanding of CF pathophysiology but also outlined the complexity of the disease. 
CFTR is 1480-aminoacids glycoprotein belonging to the adenosine triphosphate (ATP)-binding cassette 
(ABC) transporter superfamily, and it is composed of five domains [9]:  
 two transmembrane domains forming the channel pore (TMD1 and TMD2), each with six 
hydrophobic α-helix transmembrane segments (TMs);  
 two cytosolic nucleotide-binding domain (NBD1 and NBD2) involved in the ATP binding;  
 a unique regulatory domain (RD) with multiple protein kinase A (PKA)-dependent phosphorylation 
sites, that control CFTR activity as an ATP-gated ion channel.  
Moreover, CFTR presents two extracellular asparagine (Asn)-linked N-glycosylation sites between the 




Figure 1: Schematic structure of CFTR channel. Figure adapted from Hwang TC: Structural mechanisms of CFTR function and 
dysfunction [9]. 
The “gating” of the channel is a finely regulated process: the activation starts with the phosphorylation of 
R domain through the protein kinase A (PKA) and the recruitment of ATP to the NBD1 and NBD2, which 
dimerize to open the channel. The subsequent ATP hydrolysis causes the NBDs dissociation to close the 
channel [11]. 
CFTR is a cyclic adenosine monophosphate (cAMP)-regulated anion channel: in cells, high levels of cAMP 
activate the PKA that phosphorylates the R domain of CFTR to regulate the channel activity [12]. CFTR 
transport Cl- and HCO3- across the epithelium in the respiratory tract, pancreas, gastrointestinal tract, the 
biliary and sweat ducts and part of the reproductive organs [9]. 
Mutations in CFTR protein result in dysfunctional ion transport across the apical membrane at the surface 
of several epithelia, generating thickened and dehydrated secretions. In the lung, this leads to a decrease 
in the mucociliary clearance, favoring bacterial colonization and progressive obstruction of the ducts, as 




Figure 2: Panel A shows the organs that cystic fibrosis can affect. Panel B shows a cross-section of a normal airway. Panel C 
shows a cross-section of the airway of a CF patient. Figure adapted from National Heart Lung and Blood Institute (NIH) website. 
The dysfunctional ion transport across the apical membrane severely impacts the organs where CFTR is 
expressed with the respiratory system being the worst affected.  The impaired activity of CFTR in the 
airway epithelium causes dysregulation of the volume and the composition of the airway surface liquid 
(ASL). Indeed, the airway epithelial ion transport is essential to generate osmotic gradients that provide 
the driving force for transepithelial fluid movement [14]. The ASL volume is finely regulated by the airway 
epithelium and its impaired work can lead to ASL depletion, promoting mucus adhesion and chronic 




1.1.2 Classes of CFTR mutations 
Although over 2000 CFTR variants have been identified so far, pathogenicity has been demonstrated only 
for approximately 350 variants [16]. Only a relatively limited number of all the CFTR mutations are known 
to be related to CFTR channel dysfunction, whereas the functional consequences of some rare sequence 
mutations remain unknown. The CF-causing mutations have been traditionally classified in six classes [17], 
according to their final effect on CFTR (a summary of the classification is shown in Figure 3):  
 Class I: failure in protein synthesis due to frameshift or nonsense mutations; for example, G542X 
is a nonsense or stop mutation, where the introduction of a premature termination codon (or 
stop codon) results in premature cessation of translation and production of truncated CFTR 
protein. 
 Class II: unstable conformation and early degradation of the protein; this class includes F508del 
mutation and the resulting protein shows folding or maturation defects.  
 Class III: low transport of chloride through the channel due to limited channel gating caused by 
ineffectual binding of nucleotide; an example is G551D, which accounts for 2–3% of CFTR 
mutations worldwide.  
 Class IV: low ions conductance through the channel due to conductance defects, even though the 
channel is able to open and close.  
 Class V: small amount of functional and normal protein because of limited transcriptional 
regulation. 
 Class VI: destabilization at the apical membrane, leading to high turnover of CFTR at the cell 
surface.  
In 2016, De Boeck and Amaral divided the first class mutations into Class I (carrying stop-codons) and Class 
VII (which lacks mRNA transcription) [18]. Class VII mutations are considered among the most severe CFTR 
mutations: even though Class VII has the same outcome as Class I, that is the absence of CFTR protein, it 





Figure 3: Categorization of CFTR mutations in six classes. Class I, II, V and VI are responsible for a reduction of functional CFTR 
that reaches the membrane; class III and IV show a reduction of CFTR function. Picture taken from Derichs N., Targeting a 
genetic defect: cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis [17]. 
Only four CFTR mutations show a frequency of 1-3% among CF patients: G551D, W1282X, G542X and 
N1303K. The most common mutation is a deletion of the phenylalanine in position 508 (F508del), which 
shows at least one allelic frequency of around 90% among CF patients [19]. The F508del-CFTR is incorrectly 
folded, causing retention at the endoplasmatic reticulum (ER) and subsequent proteasomal degradation. 
Moreover, the small amount of mutant CFTR that reaches the membrane is unstable and shows gating 




1.1.3 Synthesis and Trafficking of CFTR 
CFTR biogenesis, as an integral transmembrane glycoprotein, begins in the endoplasmic reticulum (ER). 
The newly synthesized CFTR polypeptide chain is co-translated into the ER membrane and when it 
emerges into the ER lumen, CFTR is N-glycosylated at the Asn894 and Asn900 residues, which are located 
in the fourth extracellular loop [21].  
The N-glycosylation plays an essential role in glycoproteins intracellular processes, such as folding and 
trafficking [22], since the sugars moieties act as stabilizers and recognition targets. For CFTR, the 
glycosylation is critical for the quality control processes in the ER that checks the correct folding status of 
those proteins that are sent to the plasma membrane (PM) through the Golgi complex. The glycosylated 
immature form of wild type (wt)-CFTR can traffic to the Golgi complex, where it is processed by several 
Golgi glycosyltransferases to create the fully mature form of wt-CFTR [23].  
Cells have different quality control mechanisms that recognize the misfolded proteins and then target 
them for degradation. For CFTR, cells have several levels at which this happens [24]. 
In order to exit from ER and reach the Golgi, CFTR must undergo four ER quality control (ERQC) 
checkpoints [25], summarized in Figure 4:  
 
Figure 4: Four checkpoints for the ER quality control of CFTR. Figure taken from Farinha C. M., Control of cystic fibrosis 
transmembrane conductance regulator membrane trafficking: not just from the endoplasmic reticulum to the Golgi [23]. 
1) The first checkpoint is represented by the chaperone complexes containing Hsc70 (Heat-shock 
cognate)/Hsp70 and Hsp90 (Heat-shock protein 90) [26], able to bind the nascent CFTR in order 
to assess its conformation. This is the major mechanism for the trapping of F508del-CFTR; in fact, 
Hsp/Hsc70 is able to recognize (and strongly bind to) the exposed hydrophobic residues of the 
mutant protein, given its failure to acquire the proper conformation. 
2) The second ERQC checkpoint involves the glycosylation of CFTR and the calnexin cycle [27]. 
Calnexin, able to bind N-glycosyl residues, is a key regulator of the ER quality control system and 
its prolonged association with F508del-CFTR promotes the degradation of the mutant protein.  
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3) The third checkpoint occurs at the ER exit sites, where misfolded CFTR is retained because it 
exposes the ER retention motifs – four arginine-framed tripeptides (AFTs) [28]. 
4) The fourth checkpoint is a positive export signal (the di-acidic exit code DAD, located in the NBD1) 
that mutant CFTR fails to expose to exit ER [29].  
Proteins which are recognized as unfolded or misfolded by quality control mechanisms of the cell 
(F508del-CFTR e.g.) are almost completely retained in the ER and then targeted for premature 
degradation through the ubiquitin-proteasome pathway (UPP) [30]. 
Besides this conventional trafficking pathway, a “nonconventional” trafficking route from ER to the Golgi 
apparatus was described for CFTR [31], even though it has limited therapeutic significance. This route is 
insensitive to the checkpoints of the conventional route and exploits tubular structures migrating 
peripherally to the central Golgi [32]. With this route, the COPII (coated proteins type II) machinery takes 
both the folded and misfolded CFTR but only the properly folded protein will reach the Golgi. Through the 
COPI (coated protein I) vesicles, the misfolded protein is recycled in the ER, where the protein can repeat 
the folding process and then can be sent either to the Golgi or to the proteasome for degradation.  
The correct folding of the protein is essential not only for the ERQC machinery, but also for the CFTR 
retention at the plasma membrane.  
The levels of CFTR at the PM are regulated by three processes: anterograde trafficking (from the trans-
Golgi network to the PM), endocytosis in clathrin-coated vesicles, and recycling of the endocytosed CFTR 
[33]. Of these three processes, endocytosis and recycling are extensively regulated [34]: indeed, several 
studies show that the internalized CFTR is stored in early endosomes, which are used for the continuous 
recycling of CFTR [35], [36] from endosomes to the PM. 
Since the endocytosis of CFTR is a rapid process, if compared to its biosynthesis and maturation [37], the 
recycling of internalized CFTR is crucial to maintain a functional pool of anion channel at the membrane 
surface [38]. 
The CFTR trafficking, as well as its turnover and retention at the surface of epithelial cells, is a complex 
process in which the folding status of the protein is assessed [39]. 
Rab GTPaes, one of the largest branches of the Ras superfamily [40],  are key regulators of the intracellular 
protein transport [41] and they are also involved in the delivery of CFTR to the plasma membrane, as 




Figure 5: Regulation of CFTR trafficking and retention at the cell surface by Ras GTPases. Picture taken from Farinha C. M., 
Control of cystic fibrosis transmembrane conductance regulator membrane trafficking: not just from the endoplasmic reticulum 
to the Golgi [23]. 
Mature CFTR exits the trans-Golgi network (TGN) in vesicles belonging to the intracellular protein 
transport to reach the plasma membrane [42]. CFTR insertion into the plasma membrane is driven by the 
myosin myo5b, Rab 11 and the PDZ adaptor NHERF1 [43]. 
At the PM, CFTR must undergo the final checkpoint: if CFTR passes this last checkpoint, it can be tethered 
to the plasma membrane through the actin cytoskeleton. Otherwise, the misfolded CFTR is rapidly 
ubiquitinated and caught by the endocytic pathway [44]. At this point CFTR can be either deubiquitinated, 
refolded and recycled to the PM or sent to the lysosome via Rab7 for its degradation [44]. Interestingly, 
Rab9 and Rab11 can lead CFTR back to the TGN in the sorting endosome. On the contrary, if CFTR binds 
to Rab4 and Rab27, it is retained at the intracellular endosomal compartment, preventing its trafficking 
to the PM. 
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1.1.4 Drugs for CF 
In the 1980s, children with cystic fibrosis rarely lived beyond adolescence. Over the last decade, life 
expectancy increased, thanks to the use of antibiotics, anti-inflammatory and mucolytic drugs as 
symptomatic therapies. Nevertheless, these therapies only treat the manifestations of the disease, 
without correcting the channel defect [45]. 
At present, the disease-specific therapeutic options for CF patients depend on the type of mutation in the 
CFTR gene. Two classes of drugs are available [46] exploiting different mechanisms of action, summarized 
in Figure 6:  
 Potentiators: molecules that activate the mutant CFTR channel present at the plasma 
membrane. The only approved potentiator, the molecule VX-770 (trade name: Ivacaftor), can be 
used to treat patients having the G551D and other mutations causing gating defect.  
 Correctors: molecules that increase the trafficking of the mutant CFTR channel to the plasma 
membrane. These classes of drugs are used for patients expressing the F508del mutation 
(around 80% of CF patients). Patients homozygous for the F508del mutation are treated with 
Orkambi, a combination of the corrector Lumacaftor (trade name for the molecule VX-809) and 
the potentiator Ivacaftor.  
 
Figure 6: Site and mechanisms of action of the two classes of CFTR modulator drugs. Figure adapted from De Boeck K. Cystic 
fibrosis in the year 2020: A disease with a new face [47]. 
It has been demonstrated that a combination therapy with molecules exploiting different mechanisms of 
action is required to achieve a therapeutically relevant functional rescue of mutant CFTR [17]. For this 
reason, other combination drugs were developed, such as the drug Symdeko, the combination of the 
corrector Tezacaftor (also known as VX-661) with Ivacaftor for the treatment of patients having the 
F508del mutation on one allele and a so-called “residual function” mutation on the second allele. 
Ivacaftor produces a substantial improvement in the quality of life of CF patients. To the contrary, patients 
receiving Orkambi or Symdeko alone have a modest improvement in their conditions [48]. The new Kaftrio 
[49], a combination of three drugs (the two correctors Elexacaftor and Tezacaftor together with the 
potentiator Ivacaftor), aims at radically improving the quality of life of CF patients.   
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1.1.5 Models to study CF 
To deeply understand the molecular biology of diseases, cellular and animal models that represent the 
disease processes are needed. In recent years, advances in genetic engineering technologies helped the 
development of sophisticated models to investigate human diseases such as neurodegenerative 
conditions, cancers, and other genetic disorders. To choose the correct model, researchers need to know 
if the model system reflects the human response. Indeed, researchers must work with models that most 
closely resemble the human system. For CF, finding the correct model is complicated due to the multi-
organ nature of the disease [50].  
Modern genome editing technologies allow the researchers to build a reliable model, inserting a human 
gene into an animal species relevant to study new therapies for human disease. These innovations enable 
scientists to reveal more about the pathogenesis of a certain disease.  Nevertheless, the genetic 
modification can have undesirable effects causing, for example, the death of the animal. For this reason, 
it is extremely important to validate the genetics and the phenotype when considering a new model to 
study a biological function or disease.  
Today scientists know that, even if a perfect in-vivo model for CF is not available yet, they can compare 
studies on animals of different species [51] to understand this complex disease. Because of the difficulties 
in having a well-established in-vivo model, many studies are conducted with immortalized cell line models 
of CF and the validation is then performed in animal models or primary CF patient tissues. 
1.1.5.1 In-vitro models  
The in-vitro models can be divided into two classes: the primary cells and the immortalized cells.  
The primary cells directly derive from excised organs. To study CF, primary human airway epithelial are 
generally used. The advantage of their use is that these type of cells maintain the endogenous expression 
of CFTR, enabling the researchers to study CFTR mutation in a native environment. However, they are 
quite difficult to establish and maintain and can be used only for a limited period [52].  
On the other hand, the immortalized cells guarantee higher experimental consistency and can be grown 
for prolonged periods, obtaining a higher number of cells for further analysis. On the other hand, these 
cells could be quite different from the in-vivo tissue from which they derive.  
To study CF, several immortalized cells are commercially available, the most popular being the cystic 
fibrosis bronchial epithelium 41o- cells (CFBE41o-, shown in Figure 7). The CFBE41o- cells are a CF human 
bronchial cell line, derived from a CF patient homozygous for F508del-CFTR mutation and immortalized 
with the origin-of-replication defective SV40 plasmid (psVori-) [53]. These cells show all the ions transport 
defects caused by transfected mutant CFTR and, when cultured properly, they also form tight junctions to 




Figure 7: Picture of CFBE41o- in culture. 
1.1.5.2 In-vivo models  
In-vitro models described above show many advantages since the cells are of human origin and can be 
easily manipulated. On the contrary, animal models have their own cellular and organ physiology, which 
can differ from humans.  
Nevertheless, CF animal models are essential to understand the pathogenesis and to develop new drugs. 
The researchers in the CF field have access to multiple species that offer unique advantages, summarized 
in Figure 8.   
 
Figure 8: Organ disease phenotype in the CFTR-knockout animal models. The organs affected in CF patients are listed on the left; 
for each animal model check-marks indicate the presence of the organ-specific phenotype; question marks are symptoms yet to 
be demonstrated; X indicates the lack of organ-specific symptoms and NA means not applicable since rats don’t have the 





Three years after the discovery of CFTR gene, the first generation of CFTR-knockout mice was engineered 
[55] and  several other models followed soon after. To date, several CF models were described in literature 
[56] to study the two most common mutations in human, the F508del and G551D mutations. Even though 
CFTR-knockout mice show an intestinal phenotype, it was clear from the first model developed that they 
do not show spontaneous lung infections found in CF patients [57]. The hypothesis for the lack of 
spontaneous lung infection is that the mixed genetic background of the original strain influences the 
development of lung pathology: for example, unlike humans, mice don’t have the submucosal glands 
throughout the airways, but only in the trachea. 
Pig and ferret:  
Pigs and ferrets are the only CF in-vivo models that show the entire spectrum of CF-patients phenotype. 
As shown in Figure 8, they not only have inflammatory and infectious lung disease but show also all the 
CF-related symptoms [58]. 
However, pigs and ferrets are quite challenging species (they have prolonged gestational period and a 
long time for sexual maturation) and their maintenance requires considerable resources that significantly 
limit their widespread use in CF research.  
Rat:  
Though CFTR-knockout rats are easy to manage as compared to pigs or ferrets, it is still not clear whether 
they develop spontaneous lung infections or not. In fact, their tracheal surface shows a reduced airway 
surface liquid layer but their mucociliary clearance is efficient [59].  
Rats could represent a valuable resource to study other manifestations of the disease, such as the events 
that lead to the abnormalities of the male reproductive tract [60] or the dental complications [61], not 
developed by CF mice models. 
Rabbit:  
Since the rabbit is the newest model for CF, the phenotype is still poorly characterized. Thus far, rabbits 
showed only gut obstruction at weaning, making the rabbit suitable to study CF intestinal phenotype.  
To introduce the F508del mutation in the CFTR gene in the rabbits, the CRISPR/Cas9-targeting technology 
was used [62]. This technology has a great potential if applied to the in-vitro models of epithelia to study 




1.2 Omics  
Omics are a set of biomolecular disciplines that provide a comprehensive assessment of a class of 
molecules [63]. Omics studies require a considerable investment of time, skills and money but they also 
represent the advanced tool to investigate the chemical space composition of a living organism. Omics 
data, if correctly used, are able to highlight the biological pathways altered by disease. In recent years, 
the technological advances and development of computational tools made possible the high-throughput 
analysis of biological molecules. The results of omics studies can be used both for biomarker discovery 
and for the understanding of biological pathways associated with the disease. 
A biological pathway is a sequence of interactions between endogenous compounds in a cell that leads to 
a certain product. The aim of a biological pathway is to control the activity of the cell and its ability to 
change its behavior in response to stimuli. The correct regulation of a biological pathway is essential to 
prevent alterations that can lead to pathological states. For this reason, the study of alterations in 
biological pathways can be useful for researchers to discover new targets and thus to develop new and 
more effective drugs for a particular disease. 
Genomics was the first omics discipline to be developed. It aims at characterizing the genome, in order to 
specify the coding and the non-coding sequences, their functions and structures. The project for the 
sequencing of the human genome, concluded in 2001 [64], led to the identification of more than 20000 
protein coding genes.  
Through the transcription and the translation processes, the coding genes are translated into proteins.  
With transcriptomics, it is possible to study and quantify the expression of the transcripts within a cell. 
The transcriptome of a cell is the complete set of RNA (Ribonucleic acid) species and it comprises both the 
coding RNA (which will be translated into proteins) and the non-coding RNA (involved in several processes, 
such as post-transcriptional control) [65]. 
From a single gene, different protein isoforms can be translated, through splicing processes; moreover, 
the activity of the proteins can be regulated by post-translational modifications (PTMs), such as 
phosphorylation or methylation [66]. Given such a relevant added complexity, the exact number of 
proteoforms present in a cell is yet to be discovered [67].  
Proteins are the actual effectors of biological processes from the regulation of gene expression to the 
catalysis of chemical reactions. The central role of proteins in cell biology is highlighted by the fact that 
diseases often occur when one or more proteins show impaired function and also by the fact that most 
available drugs target proteins. Other essential molecules present in cells are the metabolites, which are 
the substrates, intermediates and products of all the biological processes. Metabolites (and their 
complexity: the metabolome) are the closest molecular representation of the phenotype.  
If the genome is static in time, protein and metabolite profiles in a cell continuously change over time, 
from tissue to tissue and in different physical or pathological conditions. Figure 9 shows how the genome 




Figure 9: Scheme of the pathway from the genotype to the phenotype. Figure adapted from Liessi N., Proteomics and 
metabolomics for cystic fibrosis research [68]. 
The study of the connections between genomics variations and alterations in the phenotype can provide 





Proteomics is the systematic characterization of the proteins expressed in biological systems, with the aim 
to detect their presence, their abundance, their modifications, and their interactions. The name 
“proteomics”, coined in 1994 during a meeting in Siena [69], defines the set of proteins codified by a 
genome, that is the entire “PROTEins profile expressed by the genOME”. 
The most broadly used technology in proteomics is LC–MS (mass spectrometry coupled to liquid 
chromatography), which is sensitive, unbiased and compatible with large-scale analysis of thousands of 
proteins in complex mixtures, such as cell lysates or biofluids [70]. Protein analysis through mass 
spectrometry (MS) was not possible until the development of soft ionization technologies, such as 
electrospray ionization (ESI), for which in 2002 John B. Fenn received the Nobel Prize in Chemistry [71]. 
Indeed, until the 1980s, the analysis of proteins and peptides was incompatible with MS, because these 
“molecular elephants” (expression taken from Fenn’s Nobel lecture [72]) could not be transferred into gas 
phase without undergoing significant degradation. Only the introduction of more appropriate ionization 
techniques allowed the gentle transfer into the mass spectrometer.  
Even though the development of soft ionization techniques, the analysis of large and intact proteins, while 
growing, it is not broadly used. The standard proteomics workflow is the “bottom-up” approach [73], 
where proteins are digested into peptides before the analysis. For this purpose, sequence-specific 
endoproteases are used, such as trypsin, which can hydrolyze the peptide chains at the carboxyl side of 
arginine or lysine, except when either is bound to a C-terminal proline. The “bottom-up” approach is 
extremely powerful, as it enables the quantification of thousands of proteins in a complex mixture.  As 
opposed to this approach, the “top-down” technique avoids the proteolytic step, analyzing intact proteins 
[74]. With this approach, it is possible to have information on the structure of the proteins, such as 
isoforms and it is generally performed on purified proteins [75].  
MS-based proteomic experiments are also very useful to identify protein interactors and the post 
translational modifications (PTMs). Since PTMs have a crucial role in hundreds of protein functions such 
as cellular signaling, control of enzyme activity, protein turnover and transport, and maintaining overall 
cell structure [76], the power of MS in this field is manifest.  




Figure 10: General workflow for LC-MS-based proteomic experiments. 
Before protein analysis, it is essential to extract the proteins from the biological matrix (e.g., tissues and 
cells) in a proper way and using the correct solvent for the lysis. Generally, the most widely used solvent 
for the lysis is the RIPA (Radioimmunoprecipitation assay) buffer, because of its efficiency in total cell lysis 
and solubilization of proteins. Indeed, this stage must ensure the efficient solubilization of as many 
proteins as possible, in order to achieve an unbiased and comprehensive analysis of the proteome. This 
step is particularly critical for membrane proteins that benefit from the use of detergents for 
solubilization. In order to prevent protein degradation, protease inhibitors are added to the lysis buffer. 
Protease activity is highly regulated in the cell: the subcellular localization of proteases is extremely 
important to control their activities. In fact, some proteases are confined within specific organelles (e.g. 
lysosomes) and only the proteins targeted to those organelles can be degraded. When cells are lysed for 
protein extraction, the membranes of the organelles are broken and proteins with different subcellular 
localization are released all at once, causing uncontrolled protein hydrolysis to peptides, thus resulting in 
decrease in the quality of MS data [21].  
For the bottom-up approach, proteins are digested into peptides using specific enzymes. To allow the 
enzyme to reach every peptide bond on which it has to work, the 3D structures of the proteins must be 
unfolded. Several types of bonds are responsible for 3D-structure. For this reason, the disulfide bonds 
between cysteine residues are normally reduced and alkylated before protein digestion.  
To increase the number of identified (and quantified) proteins, several techniques can be used. In general, 
the complexity of protein mixtures can be reduced by fractionation at protein level (using electrophoresis 




For proteomics, it is possible to predict peptide sequences and fragmentation spectra knowing protein 
sequences and enzyme cleavage patterns. Generally, thousands of spectra are acquired and, to identify 
thousands of proteins, specific software are needed to export fragmentation spectra and match them 
against in-silico data. The databases used for protein identification generally contain all the theoretical 
mass to charge ratio (m/z) values of peptides and their fragments, obtained by an in-silico digestion of all 
the proteins known for that specific organism of interest (e.g. Homo sapiens).  
1.2.1.1 LOPIT-DC for spatial proteomics 
In this work, proteomics was also extensively exploited to perform the Localisation of Organelle Proteins 
by Isotope Tagging after Differential ultraCentrifugation (LOPIT-DC) protocol. LOPIT-DC is a well-
established method for the simultaneous determination of the subcellular localization of the proteins 
from complex biological mixtures in a single experiment. The first article describing this technique was 
published in 2006 [77]. Nowadays, many different versions of this protocol have been published [78]–
[83]. 
Within the cells, proteins are spatially compartmentalized in order to precisely control cellular processes. 
Indeed, proteins are targeted to different subcellular compartments, where they fulfil specialized, 
compartment-specific functions. Three main concerns could complicate the spatial proteome profiling: 
1) proteins can be present at different subcellular locations simultaneously;  
2) proteins can move between different subcellular organelles and their function can vary 
accordingly;  
3) protein localization can change during the entire life-cycle of the cells.   
Therefore, the correct subcellular localization of proteins is crucial as it provides the physiological 
environment for their function. Protein mislocalization, together with abnormal expression in some cases, 
has been already associated with many diseases [84]–[86]. In some diseases, such as CF, an improper 
folding of a protein causes its aberrant localization. Indeed, the unfolded F508del-CFTR is retained mainly 
at the ER, thus impairing its functional activity. In this work, LOPIT-DC technique was optimized and 
applied to CF research for the first time. 
Unlike microscopy-based methods, which are generally low-throughput, LOPIT-DC provides information 
regarding the localization of hundreds of proteins, combining biochemical cell fractionation with MS-
based quantitative proteomics.  
The localization of the proteins can be assigned through multivariate statistical methods based on the 
similarity of protein distribution profile among the fractions to the profiles of well-annotated organelle 
marker proteins. Indeed proteins belonging to the same organelle would show the same (or very similar) 
distribution profile among the fractions collected after the ultracentrifugation steps.  








Figure 11: LOPIT-DC workflow. LOPIT is a quantitative mass spectrometry-based method used for the separation of organelles 
through differential ultracentrifugation steps. This workflow takes advantage of multiplex TMT-labelling (step 3) to reduce mass 
spectrometry analysis time and technical variability and SPS-MS3 for accurate quantification (step 4). Data analysis is performed 
using pRoloc (step 5) packages. Figure adapted from Geladaki A., Combining LOPIT with differential ultracentrifugation for high-
resolution spatial proteomics [87]. 
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1) Cell lysis: the number of cells must be optimized in order to obtain at least 50 µg of proteins per 
fraction. The lysis is performed using the ball-bearing homogenizer and it is one of the most critical 
step of the entire LOPIT-DC workflow. Indeed, insufficient cell lysis can lead to reduced protein 
yields per fraction while excessive lysis can compromize membrane organelles making the 
downstream subcellular fraction impossible.  
2) LOPIT-DC workflow (ultracentrifugation steps): in Figure 11, the workflow used for this work is 
shown but speeds and times should be optimized for each type of cells. 
3) Protein digestion and TMT labelling: protein digestion is generally followed by TMT (tandem mass 
tags) labelling. This is one of the quantitative proteomics techniques available in literature, 
perfectly suited for the multiplexed analysis of different biological samples. With this technique, 
the peptides are labelled with isobaric tags (their general scheme is shown in Figure 12), which 
bind the peptides at both N-termini and lysine side chains of peptides in a digest mixture. The 
labelled peptides are fragmented into the mass spectrometer and the report ions (specific for 
each TMT tag) are released. The intensities of each reporter ion are then used for the 
quantification. Each fraction deriving from the LOPIT-DC ultracentrifugation steps, is labeled with 
different TMT tags; in this way, the corresponding reporter ion quantification directly mirrors the 
abundance of that peptide in each fraction.  
 
Figure 12: Each isobaric tagging reagent has the same precursor mass and is composed of an amine-reactive NHS-ester 
group, a spacer arm and an MS/MS reporter. The reporter ions used for quantification can be released through HDC 
(higher-energy collisional dissociation) or ETD (electron-transfer dissociation) fragmentation. 
4) Peptide fractionation & LC-MS/MS analysis with SPS-MS3 for TMT quantitation: the combined 
TMT-labelled peptides are then fractionated before the SPS (synchronous precursors selection)-
MS3 analysis for accurate protein quantification and spatial resolution.   
5) Data analysis (extraction of protein profile, multivariate data analysis using pRoloc package): 
data analysis for LOPIT-DC experiments is generally performed using the pRoloc, a Bioconductor 
R package [88]. This tool creates organelle-specific profiles using known organelle markers and 
matches them to the distribution profiles of the proteins with unknown localization. In the end, 
several algorithm can be used to assign subcellular localization of proteins, such as the support 




Metabolomics is the global study of all the low-molecular-weight molecules (<1000 Da) present in a 
biofluid, cell, tissue, organ or organism in a particular physiological or developmental state [90]. The 
results of metabolomic studies provide an overview of the alterations of the upstream biological processes 
resulting from not only the genetic background but also from environmental perturbations. Anything from 
small dietary changes to elevated stress can significantly alter the composition of the metabolome.  
In the 1940s, Roger Williams [91], who analyzed urine and saliva to seek for metabolic patterns related to 
schizophrenia, performed the first “metabolomic fingerprint”. In 1971 the expression “metabolic profile” 
was used for the first time [92], when advancements in technology allowed the shifting from qualitative 
to quantitative measures of metabolites. 
As opposed to proteomics, where the molecules to be analyzed are essential similar from a chemical point 
of view, metabolomics aims at tracking simultaneously multiple small molecules types, such as lipids, 
carbohydrates, amino acids and other products of cellular metabolism. 
Due to the chemical diversity of the metabolites, LC-MS is not the only analytical technique used for 
metabolomics (as it happens for proteomics). In fact, metabolomics is also frequently performed by both 
GC-MS (gas chromatography coupled to mass spectrometry) and NMR (nuclear magnetic resonance) 
spectroscopy. The choice of the technique for the analysis depends on the experimental objective and 
sample time. Despite being one of the oldest MS-based techniques, GC-MS still offers unmatched 
performances for the identification (and quantification) of small and volatile molecules. Nevertheless, its 
use is limited because it requires the chemical derivatization of all the non-volatile biological molecules 
[93]. Even though much less sensitive than MS, NMR is the state-of-the-art technology to analyze polar 
compounds. Moreover, with NMR it is possible to perform absolute quantification of the metabolites (not 
possible with MS).  
In contrast with other studies (e.g., genomics) but in common with proteomics, there are no methods for 
the amplification of the metabolites, thus making the sensitivity a major issue in metabolomics [90].  
Before any analysis, the metabolism in the sample matrix needs to be stopped to prevent metabolites 
degradation. Since their turnover can occur within seconds [94], strategies must be put in place to avoid 
significant alterations during the sampling. The block of the metabolism reactions can be achieved by 
freezing and/or enzyme denaturation, following one of the many protocols available in literature [95], 
[96]. Generally, for cells, adding cold organic solvents can block all the enzymatic activities, while for 
tissues it is better to freeze first and then extract. The general workflow for metabolomic analysis is 




Figure 13: Scheme of the general workflow for metabolomic experiments. 
Once extracted, the metabolites must be analyzed using the more appropriate instrument able to detect 
as many metabolites as possible. Metabolites are much more challenging to annotate than proteins 
because of the lack of a genetic template. For this reason, validation of retention times and fragmentation 
spectra is often required to have confident metabolite identification.  
Untargeted approaches, generally used to generate hypotheses, focuses on acquiring and analyzing as 
many metabolites as possible to detect metabolic changes. With this approach, data can be used for 
relative quantification thus providing a trend of the distribution of both the unknown and known 
metabolites across the samples. The results of untargeted analyses can generate hypotheses that should 
be validated with targeted approaches, whose aim is to identify and quantify (absolute quantification) a 
limited number of known metabolites. Figure 14 shows the different goals of targeted and untargeted 
analyses.  
 
Figure 14: Comparison of untargeted and targeted metabolomics studies. The discovery-based untargeted metabolomic studies 
aim at global detection and relative quantitation of small molecules. Targeted metabolomics is generally used to validate results 
obtained in untargeted approaches. The aim of targeted metabolomic studies is to focus on measuring well-defined groups of 
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metabolites with opportunities for absolute quantitation. Picture taken from Schrimpe-Rutledge A. C.: Untargeted Metabolomics 
Strategies—Challenges and Emerging Directions [97]. 
The general workflow for untargeted metabolomics data analysis is summarized in Figure 15.  
 
Figure 15: Scheme of the steps for metabolite annotation. 
The first step is generally the features extraction: untargeted LC-MS metabolomic studies can detect 
thousands of signals, commonly called features [98]. Peak-picking algorithms [99]–[101] detect those 
signals that can be associated with metabolites. Since, molecules are frequently detected in electrospray 
mass spectrometry in the form of different adduct (e.g., [M+Na]+, [M+NH4]+, [M+HCOO]-), besides 
protonated or deprotonated species, these algorithms also help in the deconvolution of the observed 
features.  
Only a small portion of the detected features can be readily identified. The real bottleneck of the data 
analysis in metabolomics is the compound identification step: the m/z values are searched against 
metabolite libraries [102]–[104] to obtain a list of putative identifications. The metabolites having 
molecular weights within a specified tolerance range to the query m/z value are retrieved from the 
databases as putative identifications.  
Finally, whenever possible, the MS/MS spectra and the retention times of the putative metabolites are 
compared with the standard compound analyzed under identical conditions for the unambiguous 




1.3 Omics in CF research  
Both proteomics and metabolomics were applied to cystic fibrosis research for many applications: from 
the identification of CFTR interactors to biomarker discovery [68]. The final aim of all these studies is to 
elucidate the phenotypes resulting from CFTR mutations at both metabolomic and proteomic levels.  
Proteomics was successfully applied to study CFTR interactome to have a comprehensive overview of how 
CFTR works inside the cells. The first interactomic study was performed in 2006 by Wang et al. [106]. The 
authors exploited their newly-developed technique - the multidimensional protein identification 
technology (MudPIT) - to study the wt-CFTR interactome in different cell lines (both lung and intestine cell 
lines). Moreover, they applied the MudPIT workflow to study the different proteins present in the wt-
CFTR interactome in comparison to the F508del-CFTR interactome. In particular, they focused on finding 
differences in proteins involved in ER machinery transport. This experiment led to the identification of the 
Hsp90 cochaperone aha1 as a specific F508del-CFTR interactor.  
Other interactomic experiments were conducted to study the different interactome of wt-CFTR 
(expressed in HBE14o-) and F508del-CFTR (present in CFBE41o-) in 2015 [107]; they also studied how the 
interactome changed after F508del-CFTR rescue maneuvers. This study showed that wt- and F508del-
CFTR share 85% of their interactomes. Among the proteins that specifically interact with F508del-CFTR, 
chaperones involved in ER quality control and in protein degradation were identified. Interestingly, this 
study identified also a set of proteins involved in the endoplasmic-reticulum-associated degradation 
(ERAD) but never associated to CF (such as the proteins AUP1, SEL1L and FAF2).  
In 2018, MS-based proteomics coupled with bioinformatics tools were applied to study how F508del-CFTR 
is retained in the ER by the ERQC (ER quality control) machinery [108]. In particular, the interactome of 
F508del-CFTR at the AFT motif was investigated. As already described in Paragraph 1.1.3, the AFT motif is 
used by the cells as a signal to retain unfolded proteins in ER (the exposure of this motif is regulated by 
the folding status of the protein). Among the proteins that specifically interact with F508del-CFTR at the 
AFT motif, proteins involved in the vesicle-mediated transport were identified as well as proteins involved 
in the folding mechanism [108]. 
The last interactomic experiment was performed in 2019 [109], leading to the identification of Calpain-1 
protein as F508del-CFTR interactor at the plasma membrane. In this study, engineered immortalized 
bronchial cell line (mChery-FLAG-CFTR CFBE cells) were used to develop a particular immunoprecipitation-
based protocol containing a cross-linking agent. With this new immunoprecipitation method, the authors 
were able to select the CFTR interactome at the plasma membrane. Three proteins were selected as 
relevant interactors belonging to the NHERF1-ezrin complexes: 14-3-3 zeta, calpain-1 and importin 5. The 
particular role of calpain-1 in reducing the F508del-CFTR stability at the plasma membrane was further 
investigated: they demonstrated that a down-regulation of calpain-1 triggers a functional rescue of 
F508del-CFTR in airway epithelium.  
Proteomics was also applied to study PTMs and their influence on CFTR activity. The first studies on PTMs 
demonstrated that misfolding of the mutant CFTR impaired the PTMs-regulated activities of the channel 
[12] and only in 2019 the PTMs were described as key regulators of CFTR biogenesis and trafficking [110]. 
In particular, they studied how some PTMs can regulate the turnover of CFTR and how different is the 
PTMs landscape of CFTR with different CF-causing mutations.  Moreover, they investigated if differences 
in PTMs can have a role in CFTR rescue. Their findings showed that the amount of phosphorylation in 
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G551D and R117H mutants (having a defective ion channel activity with no effects on biogenesis) was 
comparable to the amount of phosphorylation in wt-CFTR. On the contrary, the phosphorylation at Thr421 
to Ser427 was drastically reduced for N1303K- and F508del-CFTR (both having a defective maturation), 
suggesting that these phosphorylation sites are crucial for CFTR biogenesis. 
Only few studies were performed to detect global changes in protein expression profiles in CF bronchial 
tissue.  
Two studies were performed exploiting the 2DGE/MS-based technology, which has a bias toward the most 
abundant and soluble proteins:  
I. In 2006, protein expression of bronchial biopsies derived from 9 CF patients were compared to 
those of 8 control subjects [111]; this study revealed that proteins involved in inflammation, 
infection and cellular stress response were differentially expressed.  
II. A more recent study, in 2018 [112], showed that 15 proteins were significantly dysregulated by 
the F508del mutation. The proteome of CFBE41o- cells, expressing F508del-CFTR, was compared 
to that of 16HBE14o- cells, expressing wt-CFTR.   
The first shotgun, label-free quantification of protein from total lysates of cells was performed in 2014 
[113]. The proteome of CFBE41o- cells was compared to that of 16HBE14o- cells: among the thousands of 
proteins detected  - while with 2DGE/MS methods hundreds of proteins are detectable – 349 proteins 
were found to be significantly dysregulated by the F508del mutation.   
The first (and only) quantitative proteomic study on primary bronchial epithelium cells was performed in 
this thesis work, as described in (Paragraph 4.2).  
Even though these studies provided insights into some CF-related processes, very few papers report data 
from a large-scale systematic investigation. The same happens for metabolomic studies, which were 
conducted mainly for biomarker discovery rather than to investigate basic CF pathophysiology at the cell 
level.  
The first untargeted metabolomic study was performed in 2010 [114] to pinpoint the epithelial 
dysfunction caused by CF. They used primary airway epithelium cells to compare the metabolome of CF 
patients to non-CF subjects, revealing some metabolic alterations:  
 Nucleotide metabolism, with a decrease in purine biosynthesis, essential for the control of ASL 
(airway surface liquid) volume.  
 Increase in the catabolism of Tryptophan, causing accumulation of molecules associated with 
oxidative stress.  
 Reduction of glutathione biosynthesis, a key regulator of the oxidative status of the cells.  
 Decrease in osmolytes, such as sorbitol and glycerophosphorylcoline, which have a role in the 
regulation of cell volume.  
 Low levels of glucose metabolism, possible cause of an increase in cell sensitivity to oxidative 
stress.  
Other contributions to the understanding of the molecular mechanisms of CF disease were provided by 




Further metabolomic studies were performed comparing the serum of 31 CF children to the serum of 31 
non-CF children [116]. 92 metabolites were found to be dysregulated by CF, revealing some novel 
pathways dysregulated in CF (such as cellular energy production through the β-oxidation of fatty acids) 
together with already known altered pathways (e.g. increased oxidative stress). 
The metabolome of serum was also studied to monitor the efficacy of Orkambi (the combination of 
Lumacaftor and Ivacaftor) treatment [117]. Despite the limited number of samples (only 20 patients were 
monitored after a six-month therapy), metabolites involved in lipid and aminoacid metabolisms were 
found to be altered by the treatment.  
Together with proteomics and metabolomics, transcriptomic studies were also performed to better 
understand how dysfunctional CFTR impacts on transcriptional events in CF. Both microarray and RNA-
sequencing techniques were exploited in many CF studies, with different aims:  
 to investigate transcriptional changes induced by bacterial infections [118], [119]. 
 to compare CF patients to non-CF subjects [120]. 
 to study changes associated to pharmacological treatment, such as Azitromycin in 2009 [121] or 
CF correctors/potentiators (in 2019 only with Ivacaftor to predict clinical responsiveness [122], in 
2020 the treatment with Orkambi was investigated [123]; treatment for exacerbations: in 2018 
[124]) 
 to study changes after external stimuli: oxidative stress in 2014 [125], digitoxin in 2017 [126], 
genomic variations in 2018 [127].  
All the cited studies were performed using bronchial epithelial cells, as they are the most affected by the 
impaired function of mutant CFTR in the lungs. Most of these studies detected as altered several pathways 
related to inflammation, such as NF-KB signaling [119], [120]. Interestingly, transcriptomics investigation 





1.4 LIQUID CHROMATOGRAPHY - MASS SPECTROMETRY (LC-MS) for omics 
Mass spectrometry is a powerful tool to detect and quantify biomolecules in a complex mixture because 
of its sensitivity and relatively high-throughput. MS is generally coupled to liquid chromatography (LC), 
that is a technique commonly used to separate the analytes (peptides for bottom-up proteomics and 
metabolites for metabolomics) dissolved in a solvent called “mobile phase” or eluent. With the use of 
pumps and an injection system, the eluents bring the analytes to the detection system passing through a 
“stationary phase”. The chemical proprieties of each analyte directly results in its partition between the 
stationary and the mobile phases.   
Based on the different chemistries of the interaction of analytes with the stationary and the mobile 
phases, several types of chromatographies are available for the coupling with MS. The most widely used 
chromatography for “omics” applications is the “reverse phase liquid chromatography” (RP-LC), which is 
able to separate the molecules mostly based on their hydrophobicity, generally indicated by the LogP (the 
logarithm of the partition coefficient defined as the ratio of the concentrations of the compound in a 
mixture of two immiscible solvents). In RP-LC, the analytes elute mainly based on their increasing LogP 
value, with the eluent phase composition changing over time (gradient separations).  
After sample loading into the chromatographic column, the analytes are separated and eluted through a 
gradient of elution strength in the mobile phase, usually achieved with the use of acetonitrile or methanol. 
The separation of the molecules contained in complex mixtures occurs because each of the molecules is 
eluted at a different time (corresponding to a different concentration of mobile phase), depending on its 
chemical composition. The time of the elution of a molecule is called retention time.   
Once eluted, the analytes enter the mass spectrometer, which is usually made of three main parts:  
1) Ion source, where the analytes are transferred as ions from aqueous to the gas phase. The 
electrospray ion source (the most widely used for omics applications) nebulizes the analytes in 
small droplets which are ionized by a potential difference able to confer a charge to the droplets 
[128].  
Electrospray ionization (ESI) allows both the ionization and the transfer into the gas phase of 
molecules in solution, as shown in Figure 16. In LC-MS, the electrospray is applied at the end of 
the chromatographic column, by applying a high voltage to the eluted mobile phase, causing the 
production of small, charged droplets. The evaporation of the solvent from the nebulized 
droplets results in the so-called “coulombic explosion”, with ions of the same charge ejected in 
the gas phase as  “naked” ions [129]. Only charged molecules can be analyzed by the mass 
spectrometer, while the instrument does not detect neutral molecules, which are generally 
prevented from entering the mass analyzer. 
 




2) Mass analyzer, which measures the mass-to-charge ratio (m/z) of the ions. The ability to 
separate molecules based on different m/z was first described in 1912 by Thomson, the winner 
of the 1906 Nobel Prize in physics for his studies on the conduction of electricity by gases [130]. 
There are different types of mass analyzers. Each of them is characterized by distinctive 
resolution and mass accuracy. 
The instruments used for this thesis belong to the so-called “hybrid” mass spectrometers class, 
to obtain both high mass accuracy and good sensitivity during the detection of the ions. 
In fact, they have both the quadrupole and the time of flight (TOF) mass analyzers, as illustrated 
in Figure 17. The first quadrupole (Q1) acts as a filter to select a particular m/z value. The second 
quadrupole (q2) works as a collision chamber, where the ions are fragmented. Once arrived in 
the TOF analyzer the charged molecules (either intact or fragmented) are accelerated to high 
kinetic energy and are separated along a flight tube, as a result of their different velocities, which 
depend on their mass (with lower m/z ions flying faster).  
 
Figure 17: Quadrupole-TOF analyzer scheme. Picture adapted from Aebersold R. Mass spectrometry-based proteomics [128]. 
In this work, another mass analyzer was used: the Orbitrap, shown in Figure 18. This relatively 
new (since 2006, [131]) mass analyzer is able to monitor the oscillations of the ions that orbit 
around a central spindle-like electrode with electrostatic attraction balanced by centripetal 
force. The frequency of the oscillations of the ions along the axis of the electrode is characteristic 
of the ion m/z value. 
 
Figure 18: Ions movement in the orbital analyzer. 
3) Detector: a device able to convert the arrival of the ions into a detectable and measurable ion 
current. 
The result of the combined work of these three devices is a histogram of intensities at different m/z values, 
called “mass spectrum”.  
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Most mass spectrometers have also the ability to fragment the molecule and to acquire the corresponding 
fragmentation spectrum (MS/MS or tandem MS or MS2). The fragmentation peaks produced by MS/MS 
experiments are used for the identification of the biomolecule.  
Different types of instruments, having different ion sources and mass analyzers, are currently used in the 




1.4.1 qTOF Mass spectrometers  
For all the expression proteomic experiments reported in this work, a SCIEX TripleTOF5600+ was used. 
The diagram of this instrument is illustrated in Figure 19.  
 
Figure 19: Scheme of the components of the TripleTOF5600+ instrument. 
This instrument has a series of quadrupoles aiming at filtering and focusing the ions and at removing the 
neutral molecules. This increases the sensitivity of the instrument and the signal-to-noise ratio. The first 
quadrupole is the QJet ion guide that focuses the ions before their entrance into the second quadrupole 
of the series, the Q0. In the Q0 region, the ions are focused again and only the Q1 quadrupole filters the 
ions before they enter the Q2 collision cell. In this cell, collisions with gas molecules cause the breaking of 
molecular bonds, through the conversion of the ion kinetic energy into vibrational energies of the 
chemical bonds. Finally, the ions arrive at the TOF analyzer where they are separated in time based on 
their m/z ratio.  
This instrument has two operating modes: the Data-dependent acquisition (DDA) and Data-independent 
acquisition (DIA).  
In the DDA approach, as the compounds enter the mass spectrometer, the instrument quickly scans them 
and chooses a subset of signals for the fragmentation. The choice of the instrument relies on some criteria 
previously set up in the method, which is usually based on the ions’ abundance or, particularly in 
proteomics, their charge state. In general, with this method it is possible to select a number of the most 
abundant ions for the fragmentation. The MS/MS spectra derived by the fragmentation are used for 
further identification. 
Unlike data-dependent acquisition (DDA) methods, where only a subset of a fixed number of precursor 
ions (the most abundant ones) are fragmented, Sequential Window Acquisition of all Theoretical 
fragmentation spectra (SWATH) MS (mass-spectrometry) is a data-independent acquisition (DIA) where 
all the ionized peptides are fragmented and can be identified [132]. In fact, SWATH allows the 
fragmentation of (in principle) every peptide present in a complex mixture within a broad and pre-defined 
mass range.  
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Sequential Window Acquisition of all Theoretical fragmentation spectra [133] is a label-free quantification 
method that allows a complete and permanent recording of all the fragment ions of the detectable 
peptide precursors, thus leading to the quantification of several thousands of proteins in a biological 
sample.  
The major advantage of SWATH MS is that it combines the high reproducibility and sensitivity of targeted 
methods with the huge proteome depth typically obtained with DDA MS. Thanks to its accuracy and 
reproducibility, SWATH is suited for projects with a large number of samples, which require accurate and 
reproducible quantification.  
To query the SWATH data, where theoretically all the detectable peptides in the sample can be identified, 
a library containing previously acquired data is used. The libraries are built in DDA mode and report 
information regarding the chromatographic and mass spectrometric behavior of all the detected peptides 
in the biological matrix.  
Nevertheless, the generation of a project-specific ion library makes SWATH less attractive for studies with 
a low number of samples. The other drawback of this technique is that only proteins which assays are 
reported in the IL can be quantified [134].  The quality and coverage of such a reference library are 
therefore exceedingly important.  
In the context of SWATH proteomics, an “assay” is a text string that reports the observed molecular 
information for a given peptide (accurate mass, retention time and, most importantly, its corresponding 
MS/MS fragments with their intensities). The assays reported in the library are used by the data analysis 
software to univocally link a given set of peptides to their corresponding originating protein, thus allowing 
its simultaneous identification and quantification.  
For the metabolomic analysis of this work two different instruments were used: SynaptG2 for untargeted 






Figure 20: Scheme of the components is Synapt G2 QTOF high-resolution mass spectrometer. This instrument was used in this 
work for lipidomics untargeted analysis. 
As shown in Figure 20, the QTOF Synapt G2 is a hybrid mass spectrometer, where the quadrupole selects 
and fragments the ion before they arrive at the TOF analyzer. The ion guide before the quadrupole has 
the capability of focusing the ions and removing the neutral contaminants thus increasing the sensitivity 
of the instrument. For untargeted analysis, this instrument works acquiring in MSE mode [135], where full 
MS1 scan is integrated with MS/MS fragmentation for all the precursor ions.  
For the targeted analysis present in this work a quadrupole was used. The general scheme of a quadrupole 
is shown in Figure 21.  
 
Figure 21: General scheme of a triple quadrupole mass analyzer. 
For targeted analysis, the selected molecules to be analyzed are filtered by the first quadrupole. The 
second quadrupole acts as a collision cell for the fragmentation of the selected molecules through 
collision-induced dissociation (CID). In the end, the third and last quadrupole allows the detection of only 
distinct fragment ions deriving from certain precursor ions. This configuration is called multiple reaction 




1.4.2 Eclipse for LOPIT-DC experiments 
For the LOPIT-DC experiment, the Eclipse Tribrid Mass Spectrometer was used. The major components of 
this instrument are summarized in Figure 22.  
 
Figure 22: Eclipse ion path. 
With this instrument, three different dissociation techniques (CID, collision-induced dissociation; HCD, 
higher-energy collisional dissociation; and ETD, electron-transfer dissociation) can be performed at any 
fragmentation stage, followed by the acquisition by either the ion trap or the Orbitrap mass analyzer. 
Moreover, the TMT quantification can be performed following the real-time search SPS (synchronous 
precursors selection)-MS3 workflow [137]. This approach relies on searching MS/MS spectra in real-time 
during the acquisition thus performing SPS-MS3 only for identified spectra eliminating the MS3 acquisition 





1.5 Multivariate data analysis 
Modern omics experiments generate large amount of data. Therefore, proper data analysis and proper 
statistical methods are needed to obtain trustworthy results. Because of the big amount of data, 
bioinformatics tools are essential to process this kind of data [138]. 
The general workflow for data analysis aims at integrating omics data with annotational databases, such 
as Gene Ontology (GO) [139] or Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway database 
[140] to yield functional insights into the data.  
The output of quantitative omics experiment is a data matrix where for each sample thousands of features 
(variables) are quantified. To extract information from data with multiple variables, looking at all the 
variables simultaneously, multivariate data analysis without losing any information is needed. This tool 
enables also the visualization of the matrix generated by omics. 
When a biological system is perturbed – e.g., by genetic editing or pharmacological treatment – several 
changes might be observable, in principle. Advanced data analysis methods are used to discriminate which 
changes are associated to the perturbation we applied. For this reason, further biological investigations 
are always required to validate the results of omics experiments.  
Several statistical algorithms and software have been developed in recent years to deal with the complex 
dataset generated by quantitative comparisons between two or more biological conditions. For a 
sophisticated data visualization and statistics, several software were used in this work such as 
Metaboanalyst [141], Markerview [142], and the open source Bioconductor within the R statistical 
platform [143], which requires programming experience.  
For a more accurate quantification, data must be pre-processed through normalization and scaling.  
The normalization aims at reducing technical sample-sample variability without affecting biological 
variability. There are several ways to perform normalization and the right choice depends on the 
experimental design; the main normalization techniques are:  
 Using internal standards (IS): used when a specific feature is used to calculate and apply new 
normalization factors across all the samples of the dataset. For each sample, the normalization 
factor is calculated as the ratio between the average response of the IS for all the samples and 
the response in the sample. The final normalization factor is the average of all the normalization 
factors.  
 Using total area sums: each sample is normalized so that the normalized sample has the same 
area sum calculated using all peaks. This kind of normalization is useful when most of peaks in 
the samples are expected to have similar intensities in all the samples.   
 Using the most likely ratio (MLR) [144]: used especially when a large number of features (and 
thus variables) are detected – the ratio between features are used to compute a ratio histogram 
which is aligned across samples.  
Finally, the scaling aims at reducing substantially different ranges that variables can have across the 
sample. If the original data is not scaled, the variables with the largest response will tend to dominate the 
PCA analysis. Three main scaling approaches can be used:  
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 Mean centering: after this scaling, each variable retains its original range, but its average value is 
centered at zero. 
 Autoscaling: the data is first mean centered and then divided by the standard deviation for the 
variable. The final effect is that each scaled variable has a mean of zero. 
 Pareto scaling: this is a compromise between mean and autoscaling and it is often used in data 
analysis for omics. The data is first mean centered and then divided by the square root of the 
standard deviation for the variable. 
After the pre-processing of the data, an essential tool to visualize and interpret data is the Principal 
Component Analysis (PCA). PCA is an unsupervised multivariate statistical analysis, aiming at the 
dimensionality reduction of the original multi-dimensional matrix data into a low number of dimensions, 
called principal components (PC). This reduction allows the visualization of complex dataset. PCA allows 
the recognition of trends across groups of sample within a dataset. The first principal component (PC1) 
accounts for the highest difference between the samples, PC2 (orthogonal to PC1) accounts for the second 
highest difference and so on (with PC3, PC4…). The result of this analysis is a PCA score plot where each 
sample is represented by a dot in a two-dimension space (PC1 x-axis and PC2 y-axis).   
A supervised version of PCA (the partial least squares discriminant analysis, PLS-DA) can also be used to 
identify the variables that discriminate the groups with a prior knowledge of sample groups. This 
supervised technique uses class information to improve sample preparation: PLS-DA is a one-step 
procedure that combines dimensionality reduction and discriminant analysis into one algorithm.   
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The development of new effective therapies for CF increased the life expectancy of CF patients over the 
past three decades: whereas in 1980s the median survival for CF patients was only 16 years, nowadays 
life expectancy for people with CF can exceed 40 years [145].  
To improve the activity of mutant CFTR, two strategies are essential: increasing the number of the channel 
available in the plasma membrane and its opening time. The new CFTR modulators work at both levels 
separately: the potentiators aim at increasing the open channel probability, while the correctors improve 
the folding and, thus, the trafficking of the mutant CFTR at the plasma membrane.  
As discussed in the introduction, the combination of molecules exploiting different mechanisms of action 
is needed to achieve a therapeutically relevant rescue of CFTR activity. Indeed, it is not sufficient that an 
adequate amount of mutant CFTR reaches the PM, it should also work properly when there.  
The new CFTR modulators – both the correctors and the potentiators – have not the same clinical 
outcomes for all the mutations. For example, both the Symdeko and the Orkambi can be used for the 
treatment of CF patients homozygous for F508del-CFTR mutation [146]. However, none of these drugs is 
sufficiently effective in CF patients carrying a single F508del-CFTR allele and a second CFTR mutation that 
does not respond to the current CFTR modulators therapy [147].  
Despite all the recent progress in CF therapy, there is still work to be done in order to help all the people 
with CF benefit from the new modulators. For this reason, expanding the portfolio of molecules for CF 
treatment could be extremely useful to help CF patients in living longer and healthier lives.  
To expand the portfolio of molecules available for CF patients and exploiting different molecular 
mechanisms of action, finding new targets for CF pharmacological treatment would be extremely useful.  
For this reason, the aim of this work is to use omics experiments to find new potential targets for CF 
pharmacological treatment. For this purpose, omics were used to provide an insight into the changes in 
the cell molecular space associated with successful CFTR rescue maneuvers. The rescue was achieved by 
the use of drugs or by selectively silencing the expression of other proteins, able to improve the trafficking 
of CFTR itself to the plasma membrane. The general rationale for the project follows. 
If, by using omics, we are able to monitor with a sufficient analytical depth the chemical space composition 
of proteins and metabolites within the cell and we are able to accurately monitor their alterations 
following CFTR rescue, then we will gain a crucial understanding of how, at the deepest biochemical level, 
the cell itself is reacting to the rescue. For example, if, with proteomics, we identify a set of proteins that 
are downregulated following CFTR rescue, we can then hypothesize that this association works in both 
ways. Perhaps, by inhibiting the action of those same proteins, we will favor the rescue itself.  
Two different CFTR rescue strategies were used:  
1) We first used siRNA to selectively silence a set of proteins, named now “Primary targets”, whose 
inactivation is known to be associated with a positive CFTR rescue [148]. The resulting proteins 
and pathways significantly altered by the genetic rescue were investigated to find new potential 
targets. Some new target candidates were selected and compounds aiming at their inactivation 
were first tested on CFBE41o- cells and then on the bronchial epithelium (BE) primary cells to 
validate the findings. The BE primary cells were also analyzed to detect proteins (and pathways) 
altered by the disease. 
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2) We then used a pharmacological approach to obtain the rescue: we incubated CFBE41o- cells with 
a set of drugs and drugs combinations, including Kaftrio, which are currently used by CF patients 
[149]. We then used MS to monitor the corresponding alterations on the cell lipidome in response 
to these stimuli.  
Finally, we applied a very advanced omics investigation that was never used before for CF research: to 
monitor how a pharmacological rescue of CFTR alters the subcellular localization of thousands of proteins 
within CFBE41o- cells we thus used the LOPIT-DC workflow.  
A scheme of all the experiments performed in this work is shown in Figure 23.  
 
Figure 23: Summary of all the experiments performed in this thesis work.  
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3.1 Creation of the ion library for CF research  
As described above (Paragraph 1.4.1) SWATH proteomics relies on ion libraries for protein quantification. 
The Pan Human ion library, created by Rosenberger and colleagues [150], currently represents the state-
of-the-art tool for this kind of analysis on human samples. Despite its outstanding quality, the Pan Human 
ion library lacks assays for several proteins crucial for the CF biology, including CFTR. To gain a better 
understanding of CF disease, a specific ion library was built [151]. 
For this analysis, the most popular in-vitro model to study CF was used, e.g., the CFBE41o- cells. Moreover, 
to be more specific, the BE primary cells were also used. The general workflow to create the CF-specific 
ion library is summarized in Figure 24.    
 
Figure 24: Schematic workflow for the creation of the ion library. 
With the aim of increasing the total number of detected proteins, two kinds of fractionations were used, 
both at protein and peptide levels. This double fractionation strategy was possible only in CFBE41o- cells, 
as they grow quickly and continuously and it is possible to extract large amounts of proteins. For the BE 
primary cells, only one fractionation method was used instead.  
3.1.1 CFBE41o- cell cultures  
In order to minimize possible differences due to clonal variability, three different CFBE41o- cell 
populations were pooled: CFBE41o- stably over-expressing the F508del CFTR mutation, or the wt-CFTR 
allele, and isogenic CFTR null cells (CFBE41o-, null). CFBE41o- cells were cultured, transfected and grown 
to confluence on 60-mm diameter dishes and then lysed in RIPA buffer added with complete protease 
inhibitor (Roche). Cell lysates were subjected to centrifugation at 15000xg at 4°C for 10 min and 
supernatant protein concentration was measured using a BCA assay (Euroclone). Equal amounts of two 




3.1.2 Fractionation at protein level and in-gel digestion  
A fraction of the total cell lysate of CFBE41o- was separated by One-Dimensional Gel Electrophoresis 
(1DGE). A total of 720 μg of the pooled lysate were separated (60 μg per 12 lanes) onto gradient 4-20% 
Criterion TGX Precast gel (Bio-rad laboratories Inc). The gel was fixed and colored with Novex Colloidal 
Blue Staining Kit (Thermo Sci.). Each lane was cut into 16 slices and in-gel digestion [152] with trypsin was 
performed. 
Briefly, the gel was placed on a glass support to cut gel lanes into 16 slices. Using a scalpel, the gel slices 
were crumbled in small pieces of about 1-2 mm and placed in a 1.5-mL tube. As a first step, 100 μL of 
destaining solution (50% 50 mM ammonium bicarbonate / 50% acetonitrile) were added to each tube, 
incubated for 10 minutes under mild shaking, for the removal of the Coomassie dye. The destaining 
solution was removed and the destaining step was repeated as described before, in order to achieve a 
complete removal of dye. The reduction of disulfide bonds was obtained by incubating the samples at 
56°C with 100 μL of 10 mM dithiothreitol in digestion buffer (50 mM ammonium bicarbonate in water, pH 
8) for 1 hour. The reducing solution was discarded and the pieces of gel were washed with 100 μL of 
digestion buffer. The digestion buffer was removed and the gel pieces were incubated for 45 minutes in 
the darkness with 100 μL of alkylating solution (55 mM iodoacetamide in digestion buffer). After 
discarding the iodoacetamide solution, gel pieces were washed twice with 100 μL of digestion buffer for 
10 minutes and then incubated for dehydration with Acetonitrile under shaking. The Acetonitrile was 
removed and the gel pieces were left evaporating for about 30 minutes under the hood. Each sample was 
incubated with 1 μg of trypsin dissolved in digestion buffer (enzyme concentration of trypsin solution 12.5 
ng/µL) overnight at 37°C. 
3.1.3 Protein enrichment with ProteoMiner kit 
The Proteominer enrichment strategy (Biorad) was used [153], following the protocol suggested by the 
vendor. In short, protein concentration from CFBE41o- lysates was adjusted to 20 mg/mL by using Amicon 
Ultra centrifugal filter devices (3KDa cutoff, purchased from Millipore, USA). Proteominer medium was 
first activated with PBS (150 mM NaCl, 10 mM NaH2PO4, pH 7.4, 0.2 mL) and a total of 0.14 mL of protein 
solution was loaded and incubated for 2 hours. The column flow-through was removed and collected, 
along with two additional washes with 0.2 mL PBS. Proteins were then eluted eight times with 0.02 mL of 
8 M urea, 5% CH3COOH, 2% CHAPS. In-solution digestion (Paragraph 3.1.4) was then performed on both 
wash and eluted fractions.  
3.1.4 In-solution digestion 
The volume corresponding to 50 µg of proteins sample was reduced with 10 µL dithiothreitol (DTT) 100 
mM at 56 °C for 30 minutes, then alkylated with 30 µL of iodacetamide (IAA) 100 mM for 20 minutes in 
the dark. Protein content was then precipitated in cold (-20 °C) acetone overnight at -20 °C. To remove 
acetone, centrifugation at 15000xg for 30 minutes at 4 °C was performed. The supernatant was discarded 
and the pellet was dried under nitrogen stream before an overnight trypsin digestion at 37 °C in digestion 





3.1.5 Fractionation at peptide level  
Tryptic peptides deriving from in-solution digestion (Paragraph 3.1.4) were fractionated offline with the 
high pH/low pH strategy [154]. This fractionation was performed using Oasis solid-phase extraction (SPE) 
columns, following the instructions provided by the vendor. Briefly, after the activation and equilibration 
of the column resin, the peptides were loaded on the column. After the desalting of the peptides, a total 
of 8 fractions of peptides were collected by eluting the sample with 500 µL of 0.1% TEA solution with 
increasing acetonitrile concentration (5%, 7.5%, 10%, 12.5%, 15%, 17.5%, 20% and 50%).   
3.1.6 BE primary cell cultures and lysis 
Human primary bronchial epithelial (BE) cells were obtained from individuals undergoing lung transplant. 
For this study, cells were obtained from four CF patients (BE86, BE91: patients with F508del/F508del 
genotype; BE29: patient with F508del/R553X genotype; BE148: patient with R1006C/M1V genotype) and 
four non-CF donors (BE61: patient with bronchiectasia; BE65: patient with idiopathic pulmonary fibrosis; 
BE147, BE121: patients with pulmonary emphysema). The collection and processing of human cells were 
approved by the local ethics committee, and written informed consent was obtained from all patients.  
BE primary cells were cultured, transfected and then lysed in RIPA buffer added with complete protease 
inhibitor (Roche). Cell lysates were centrifuged at 15000xg at 4°C for 10 min; the supernatant was 
collected and the protein concentration was measured using a BCA assay (Euroclone). 50 µg proteins from 
each sample (both CF and non-CF) were pooled together for nanoLC-MS/MS analysis.  
3.1.7 nanoLC-MS/MS analysis (DDA mode)  
Dried tryptic peptides (from both CFBE41o- and BE primary cells, for a total of 40 samples) were dissolved 
in 150 µL of 3% acetonitrile (ACN) + 0.1% formic acid (FA) for mass spectrometry coupled to liquid 
chromatography (LC-MS/MS) analysis. The peptides were analyzed on a 5600+ TripleTOF instrument 
(SCIEX) coupled to a NanoAcquity LC system (Waters, Milford, MA, USA) and  working in nanospray mode 
with a NanoSpray III ion source. The peptides were loaded and desalted on a trapping column (180 µm × 
20 mm Acquity C18) for 4 min at 4.0 µL/min flow rate (1% ACN + 0.1% FA), and then separated on a PicoFrit 
C18 column (75 μm x 25 cm, from NewObjective Inc., Woburn, MA, USA). The peptides were eluted with 
a 2-h linear gradient at 300 nL/min (from 3% to 45% of ACN in water + 0.1% FA); the column was washed 
with 90% ACN and then equilibrated for 18 min to 3% ACN. 
DDA (Data-Dependent Acquisition) spectra were collected over the two-hour gradient. Peptides with 
charge states 2+ to 5+ showing an intensity higher than 150 counts were selected as precursors for MS/MS 
acquisition. A survey spectrum (400-1250) was acquired for 250 ms, followed by 40 DDA MS/MS 
experiments (100-1500 m/z, 100ms accumulation time each).  
3.1.8 Data analysis for protein identification 
Raw DDA data from nanoLC-MS/MS analysis were analyzed with ProteinPilot software (SCIEX) using the 
Paragon algorithm [155]. All the DDA spectra were searched against a reviewed Homo sapiens database 
reporting 20303 proteins and downloaded as FASTA file from Uniprot 
(http://www.uniprot.org/proteomes/ UP000005640) on January 3rd, 2018. A False Discovery Rate (FDR) 
[156] analysis was performed against a decoy version of the same database and identifications at 1% FDR 
at spectrum level were retained and with a minimum threshold of 90% in peptide confidence. 
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3.1.9 Interaction maps 
All the interaction maps present in this work were created using an open source tool available online 
called STRING (acronyms for Search Tool for the Retrieval of Interacting Genes/Proteins v.11.0, 
https://string-db.org/) [157].  
The parameters used to detect possible interaction in the annotated, high-quality database of Homo 
sapiens were set in the “Data Settings” tab as follow:  
 Meaning of network edges: evidence. 
 Active interaction sources: Textmining, Experiments, Databases, Co-expression, Co-occurrence. 
 Minimum required interaction score: high confidence (0.7).  
 Display simplifications: disable structure previews inside network bubbles and hide disconnected 
nodes in the network. 
With this tool, it is possible to obtain interaction maps showing the proteins as nodes connected by edges 
with different colors, corresponding to the different types of evidence used to show the interactions 
(yellow line indicates a textmining evidence; pink is used for experiments evidence; light-blue for 




3.2 Proteomics profiling of BE primary cells (CF vs non-CF) 
3.2.1 Sample preparation  
BE primary cells deriving from lung transplant were cultured and lysed as described above (Paragraph 
3.1.6). Protein content was digested following the in-solution digestion, already described (Paragraph 
3.1.4). 
3.2.2 nanoLC-MS/MS analysis (SWATH)  
Dried peptides deriving from trypsin digestion were dissolved in 150 µL of 3% acetonitrile (ACN) + 0.1% 
formic acid (FA) for mass spectrometry coupled to liquid chromatography (LC-MS/MS) analysis. The 
peptides were analyzed on a 5600+ TripleTOF instrument (SCIEX) coupled to a NanoAcquity LC system 
(Waters, Milford, MA, USA) and  working in nanospray mode with a NanoSpray III ion source. The peptides 
were loaded and desalted on a trapping column (180 µm × 20 mm Acquity C18) for 4 min at 4.0 µL/min 
flow rate (1% ACN + 0.1% FA), and then separated on a PicoFrit C18 column (75 μm x 25 cm, from 
NewObjective Inc., Woburn, MA, USA). The peptides were eluted with a 2-h linear gradient at 300 nL/min 
(from 3% to 45% of ACN in water + 0.1% FA); the column was washed with 90% ACN and then equilibrated 
for 18 min to 3% ACN. 
For SWATH acquisitions, 1.66 µg of peptides were loaded on the chromatographic column. Precursor ion 
selection was done in the 400-1250 m/z range, with a variable window width strategy (7 to 50 Da). After 
a full range survey scan of 250 ms, 100 consecutive SWATH experiments (100-1500 m/z) were performed, 
each lasting 25 ms. 
3.2.3 Data analysis for SWATH label-free quantification  
The DIA spectra were searched against our modified Pan Human ion library [151], using only non-shared 
peptides. For the quantification, the following criteria were used: minimum peptide confidence 90%, 50 
ppm maximum mass tolerance, 60 min maximum RT tolerance, 6 MRM transitions per peptide and 
modified peptides were not allowed. 
Raw data were imported in MarkerView software and normalized with the most likely ratio (MLR) method 
[144]. The normalized data were pre-processed with logarithm weighting and Pareto scaling [158].  For 
statistical analysis, one-to-one comparisons were performed using an un-paired, 2 tails t-test, considering 
a p-value < 0.05 as significant. Moreover, according to the resulting t-value, the significantly dysregulated 
proteins were divided into either up- or down-regulated.  
3.2.4 Pathway analysis  
In this work, two different tools were mainly used for the pathway analysis: Reactome and GOrilla. 
Reactome [159] is an open-source, manually curated and peer-reviewed pathway database. It provides 
bioinformatics tools for the visualization, interpretation and analysis of pathway knowledge. The user can 
insert a list of proteins (generally the significantly up/down-regulated proteins, resulting from a proteomic 
experiment) and Reactome gives the user a graphical map and the information of the pathways in which 
the inserted proteins are involved in. The pathways are ranked according to the FDR value (probability 




Using the bioinformatics tool called GOrilla [160], the user can supply two lists of unranked proteins (the 
ranking of both lists does not affect results): the target and the background sets. The software is able to 
search for the pathways that are enriched in the target set compared to the background set using the 
standard Hyper Geometric statistics [161]. Selection of an appropriate background is therefore very 
important and could be challenging in high-throughput studies. In proteomics, the background list can be 
the complete set of proteins known to be expressed in an organ/tissue/cell line. This is very important 
since only a fraction of proteins are expressed in a given tissue [162] and only a subset of proteins can be 
quantified in a single proteomic experiment. In the present work, all the quantified proteins in each 
experiment were set as background list and the p. value threshold was set at 10-3. The list of the 







3.3 Proteomics profiling of CFBE41o- cells after gene silencing 
3.3.1 CFBE41o- cell culture, gene silencing and evaluation of CFTR rescue 
For this study, CFBE41o- stably expressing F508del-CFTR and the halide-sensitive yellow fluorescent 
protein (HS-YFP) were used [148]. The gene silencing of selected proteins was performed by reverse 
transfection on CFBE41o- cells expressing F508del-CFTR and the HS-YFP using 10 nM (final concentration) 
siRNAs and lipofectamine 2000 as transfection agent. 
In this experiment, five different F508del-CFTR expressing CFBE41o- cells groups, in five independent 
biological replicates, were prepared and incubated for 48 hours: the control group (treated with dimethyl 
sulfoxide, DMSO) and groups treated with siRNA against four different proteins:  
 RNF5 (a ubiquitin ligase involved in recognition of CFTR folding defect [148]). 
 FAU (a ribosomal protein whose biological functions are still largely unknown [163]). 
 LRRC59 (a nuclear protein known to be involved in nuclear import of exogenous fibroblast growth 
factor 1 [164]). 
 PHF15 (an E3 ubiquitin-protein ligase involved in protein ubiquitination pathway [165]). 
Evaluation of CFTR protein expressed at the plasma membrane was done by performing a cell surface 
biotinylation assay, followed by immunoprecipitation of biotinylated proteins and western blot analysis 
[166] on total cell lysates. With this assay, it is possible to look for changes in band C (fully glycosylated 
mature CFTR) and compare it to band B (core-glycosylated immature CFTR). A comparison between 
lysates of CFBE41o- cells expressing F508del-CFTR following different treatments (siRNAs and/or DMSO) 
and lysates of CFBE41o- cells expressing wild type CFTR was performed.  
3.3.2 YFP-based functional assay 
YFP-based assay was performed to evaluate the effect of F508del-CFTR functional rescue after gene 
silencing. The assay was performed following a well-established protocol [166], using CFBE41o- cells that 
express F508del- CFTR together with a yellow-fluorescence protein (YFP)-based halide sensor.   
At the time of the assay, cells were washed with PBS and then incubated for 25 min with 60 μL of PBS plus 
forskolin (20 μM). For CFTR activity determination, cells were transferred to a microplate reader (FluoStar 
Galaxy; BMG Labtech, Offenburg, Germany). The plate reader was equipped with high-quality excitation 
(HQ500/20X: 500 ± 10 nm) and emission (HQ535/30M: 535 ± 15 nm) filters for YFP (Chroma Technology). 
Each assay consisted of a continuous 14-s fluorescence reading with 2 s before and 12 s after injection of 
165 μL of an iodide-containing solution. Data were normalized to the initial background-subtracted 
fluorescence. To quantify the rate of fluorescence change, the final 11 s of the data for each well were 
fitted with an exponential regression function to extrapolate initial slope (dF/dt). Statistical significance 
was assessed by parametric ANOVA, followed by Dunnett’s multiple post-hoc test, which is generally used 







3.3.3 Sample preparation and data analysis 
CFBE41o- cells after the gene silencing and the evaluation of CFTR rescue, were lysed and their protein 
content was digested as already described (Paragraph 3.1.4). The corresponding tryptic peptides were 
analyzed following the nanoLC-MS/MS workflow for SWATH quantitative proteomics (Paragraph 3.2.2, 
Paragraph 3.2.3).  
The corresponding raw data were imported in MarkerView software and normalized with the most likely 
ratio (MLR) method [144]. The normalized data were subsequently scaled with logarithm weighting and 
Pareto scaling [158].  For statistical analysis, one-to-one comparisons were performed using an un-paired, 
2 tails t-test, considering a p-value < 0.05 as significant. Moreover, according to the resulting t-value, the 
significantly dysregulated proteins were divided into either up- or down-regulated.  
3.3.4 Selection of target candidates  
To select new target candidates an extensive literature search was conducted to study the role of the 
proteins (and pathways) altered by the gene silencing, using the free search engine PubMed [167], [168].   
Four parameters were then taken into account to select appropriate modulators:  
1) Biological activity: the modulator must efficiently act on its target(s).  
2) LogP: this parameter is the index of the lipophilicity of a molecule and it was taken into account 
in order to select modulators that were soluble in the medium used to culture CFBE41o- cells. 
3) Safety: the modulators should have no reported adverse effects.  
4) Availability: the modulators to be tested must be commercially available.  
PubMed was used to study the role of the proteins that were significantly altered by the gene silencing 
and how they could be related to CFTR rescue. Moreover, two databases were interrogated to select the 
appropriate modulators that showed all the criteria described above: ChEMBL [169] and DRUGBANK 
[170].   
PubMed, Uniprot [170] and REACTOME [159] database were used to study proteins involved in the 
pathways significantly altered by the gene silencing. Among these proteins, CFTR interactors were 
searched using STRING (refer to Paragraph 3.1.9) in order to select target candidates that were searched 





3.4 Lipidomics profiling of CFBE41o- after incubation with drugs  
3.4.1 Cell cultures, incubations with drugs and CFTR rescue evaluation 
Selected CFBE41o- cells over-expressing F508del-CFTR were cultured until confluence and treated with 
vehicle alone (DMSO) or with the following drug (or combination of drugs) concentrations: VX-809 (3 μM), 
VX-661 (10 μM), VX-770 (5 μM), VX-445 (3 μM), VX-809/VX-770, VX-661/VX-770, VX-445/VX-770, VX-
661/VX-445, VX-661/VX-445/VX-770. To ensure reproducibility, six independent experiments were 
performed using 5 million cells per condition. Cells were harvested in PBS, pelleted, lysed (Paragraph 
3.1.6) and CFTR rescue was measured (Paragraph 3.3.2).  
3.4.2 Lipid extraction  
Cells pellets were resuspended with H2O (50 μL), transferred to glass vials, and added with 1 mL 
isopropanol spiked with C17 Ceramide (1 μM) as internal standard. The samples were then vortexed for 
10 minutes and sonicated for 10 minutes at room temperature (RT). After a centrifugation step (at 20000 
x g for 20 minutes at RT), the first supernatant was carefully collected (Named A) and the pellets were re-
extracted with 100 µL of methyl-tert-butyl ether (MTBE) /methanol (50:50 v/v). After vortexing for 10 
minutes and sonicating for 10 minutes at RT, another centrifugation step (at 20000 x g for 20 minutes at 
RT) was performed and the second supernatant was collected (Named B). Supernatants A and B were 
then pooled and dried under nitrogen stream. All the samples, including procedure blanks, were extracted 
following this protocol. 
3.4.3 LC-MS/MS analysis for untargeted lipidomics 
The dried lipids extracts were dissolved in 200 µL of methanol/chloroform (9:1, v/v) for LC-MS/MS 
analysis. The whole sample set (a total of 64 samples) was split into 4 batches and analyzed by high-
resolution LC-MS/MS, using a well-established method for untargeted lipidomics [171]. For each batch 
quality control (QC) samples, prepared pooling together 5 µL for each batch, were prepared and analyzed 
together with the samples within each batch. 
The lipidomics analysis was performed on an ACQUITY UPLC system coupled to a Synapt G2 QTOF high-
resolution mass spectrometer (Waters, Milford, MA, USA), acquiring both in positive (ESI+) and negative 
(ESI−) ion modes. Lipids separation was performed with a reverse-phase CSH C18 column (1.7 μm internal 
diameter; 2.1x50 mm, Waters). Eluents were acetonitrile/water (60:40 v/v) with ammonium formate 10 
μM (Eluent A) and isopropanol/acetonitrile (90:10 v/v) with ammonium formate 10 μM (Eluent B). 
Injection volume was 3 and 5 μL for ESI+ and ESI- respectively. The flow rate was set on 0.450 mL/min, 
the column was kept at 50 °C. Samples were eluted with the following gradient profile: 0.0 -1.0 min 10 % 
B; 1.0 – 4.0 min 10 to 60 % B; 4.0 – 8.0 min 60 to 75 % B; 8.0 – 8.5 min 75 to 100 % B; 8.5 – 10.0 min 100 
% B and 10.0 – 10.1 back to 10 % B. The column was then reconditioned for 1.9 min. The total run time 
was 12 min. Scan range was set from 50 to 1200 m/z. Cone voltage was set at 35 V. Source temperature 
was set to 90 °C, desolvation gas and cone gas flows were set to 800 and 50 L/h respectively, desolvation 
temperature was set to 400 °C. Data were acquired in MSE mode, alternating MS and MS/MS scans [172]. 
The scan time was set to 0.3 s, low collision energy was set to 4 eV and 13 high collision energy was 
ramped from 25 to 45 eV. Leucine enkephalin (2 ng/mL) was infused as lock mass for real-time spectra 




3.4.4 Targeted ceramide and LysoPC analysis  
To confirm the findings of untargeted lipidomics, ceramides were also quantified in a targeted 
experiment, by using a triple-quadrupole instrument (Xevo-TQMS, Waters) coupled to an ACQUITY UPLC 
(Waters) chromatographic system, following a dedicated method [173]. Three Lyso PCs were quantified 
by using the same general microLC-MS/MS method and adding the three corresponding MRM 
experiments (496  184, 524  184 and 52 184 for Lyso PCs 16:0, 18:0 and 18:1 respectively). The 
collision energy was set to 25 eV and cone voltage was set to 30V. 
3.4.5 Evaluation of cell susceptibility to pro-apoptotic stimuli 
CFBE41o- cells stably expressing F508del-CFTR were plated at low density (10,000 cells/well) on proper 
96-well plates. After 24 hours, the pharmacological treatment was performed in the absence or in the 
presence of different concentrations (1 – 10 μM range) of Etoposide to induce cell apoptosis. The 
following day plates were washed three times with DPBS to remove dead cells, cell nuclei were 
counterstained with Hoechst 33342 and propidium iodide to visualized total and apoptotic cells, 
respectively. Plates were imaged with a 10X air objective using the Opera Phenix (PerkinElmer) high-
content screening system. The excitation of Hoechst 33342 signal was at 405 nm and the emission at 435-
480 nm. The propidium iodide signal was excited at 560 nm and the emission was measured at 570-630 
nm. Data are expressed as means ± SEM, n = 8. Reproducibility of results was confirmed by performing 
three independent experiments. Statistical significance was tested by parametric ANOVA, followed by the 
Dunnett’st multiple comparisons test. 
3.4.6 Data analysis and statistics 
The observed features for both ESI+ and ESI- polarities were extracted from the RAW data, integrated and 
re-aligned over all the runs by using the Markerlynx software (Waters, Inc.). The following parameters 
were set: mass range from 200 to 1200 m/z, retention time (RT) range from 1 to 10 minutes, minimum 
intensity 4000 ion counts, m/z tolerance for extracted ion current 0.03 m/z, RT tolerance 0.03 min. 
Background ions observed in procedure blank and blank runs above the same threshold were 
automatically excluded by the software, using a background exclusion list. Exogenous d18:1/17:0 
ceramide was used as internal standard, and it was observed as [M+H2O+H]+ and [M+HCOO]- adducts for 
ESI+ and ESI- ion modes respectively with RT 5.47±0.03 min. The m/z values of the drugs were excluded 
from the peak picking process, even though the cell pellets were previously washed before lipid 
extraction.  
The samples from all the four acquisition batches were realigned using this ceramide as reference. The 
obtained datasets for ESI+ and ESI- were then merged in a final (1571 features X 42 samples) Excel file and 
analyzed using Metaboanalyst [141] web-based software. The missing values were automatically replaced 
with the minimum value of each given feature in the corresponding column. The dataset was then 
normalized by the sum of all the observed features, log transformed and Pareto scaled [158] for 
multivariate data analysis. Both the unsupervised (Principal Component Analysis – PCA) and supervised 
(Partial Least Squares Discriminant Analysis – PLS-DA) analysis methods were used, with the aim to 
identify changes in the global lipidomic profiles. The cross validation of PLS-DA analysis was performed by 
using the leave-one-out algorithm [174], searching over 5 principal components. Variable Importance in 
Projections (VIP) score for PLS-DA was calculated over component 1. Cluster analysis was done using 
heatmaps, by applying Euclidean distance measurement and Ward algorithm [141] to normalized data. 
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Correlation analysis among the features was performed using Pearson r as distance measure [175]. 
Pathway analysis was performed on annotated data, using their HMDB [176] identifier. Hypergeometric 
test was used for overrepresentation analysis and Relative-betweenness Centrality was used for Pathway 
Topology Analysis on the KEGG [177] pathway library for Homo Sapiens. 
For binary comparisons, Volcano plot analysis was used to select features based on their observed fold 
change between the treated Vs control groups (≥1.5) and their FDR adjusted p-value based on a t-test 
(p<0.05). For univariate data analysis, both 2 tailed unpaired t-tests and one-way analysis of variance 
(ANOVA) were performed using GraphPad Prism (GLS Biotech). Dunnett’st post –hoc test was used to 
compare all groups with each other. 
3.4.7 Features annotation  
The relevant features, selected from VIP scores and t-tests from Volcano plot analysis, were manually 
annotated searching them against the LipidMaps database [178], considering only the following possible 
adduct species: [M+H]+, [M-H2O+H]+, [M+NH4]+, [M+Na]+ for ESI+ and [M-H]-, [M+HCOO]- for ESI-, allowing 
0.01 m/z as maximum allowed tolerance for both polarities. The resulting list of proposed matches was 
then manually scrutinized, taking into account accurate mass and MS/MS data, beside the consistency of 
observed adduct species and retention time  [179]. None of the proposed annotations was confirmed with 
the use of an authentic analytical reference standard, so, based on current guidelines for reporting data 
in metabolomics [178], lipid IDs should thus be considered putative.  
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3.5 LOPIT-DC experiments  
These experiments were conducted in Cambridge, where I spent five months, hosted by Prof. Lilley’s lab.  
LOPIT-DC [87] workflow was applied to the CFBE41o- cells to monitor the protein localization changes 
associated with CFTR rescue in order to pinpoint those proteins which could be detrimental (or beneficial) 
to the functional rescue of the channel. The entire experimental procedure (already described in 
Paragraph 1.2.1.1) is summarized in Figure 25.  
 
Figure 25: LOPIT-DC workflow applied to the CFBE41o- to detect proteins with different subcellular localization after the 
treatment with VX-809. 
3.5.1 Cell cultures, VX-809 treatment and ultracentrifugation steps  
Selected CFBE41o- cells over-expressing F508del-CFTR were cultured until confluence as already 
described (Paragraph 3.1.1). For this experiment, 70 million cells per sample are needed. Three 
independent biological replicates were prepared, processing together the treated with its control in order 
to decrease technical variability. For each replicate, the treatment was performed incubating the cells 
with medium containing either the VX-809 1 µM or the vehicle (DMSO, used as control) for 24 hours.  
Cells were harvested with TrypLE Express Enzyme (Gibco) and pelleted at 300xg for 7 minutes at 4°C. Cell 
pellets were suspended in 5 mL of a gentle lysis buffer (0.25M sucrose, 10mM HEPES pH 7.4, 2mM EDTA, 
2mM magnesium acetate, protease inhibitors). Cells were then lysed using a pair of 1 mL syringes in a 
ball-bearing homogenizer (Isobiotec): each aliquot of cells suspension was passed through the 
homogenizer chamber 30 times using a 18 µm ball-bearing clearance, keeping the homogenizer on ice. 
Cell lysates were processed following the LOPIT-DC workflow [87], where after every centrifugation step, 
the supernatant is collected and subjected to the following centrifugation step.  The speeds and times for 




Fraction name Speed (xg) Time (min) 
Whole cell removal 200 5 
P1 1000 10 
P2 3000 10 
P3 5000 10 
P4 9000 15 
P5 12000 15 
P6 15000 15 
P7 30000 20 
P8 79000 43 
P9 120000 45 
SN 120000 SN  
 
Table 1: Speed and times of the differential centrifugation steps of the LOPIT-DC workflow. P=pellet and SN=supernatant.  
After the removal of unlysed cells (essential to prevent alterations in the downstream analysis), a total of 
ten fractions were collected for each sample. The protein content of the supernatant fraction was 
precipitated with incubation with chilled acetone (8xV) at -20 °C overnight.  
The ten pellets were solubilized using different volumes of membrane solubilizing buffer (MSB, 8 M Urea, 
0.2% SDS, 50 mM HEPES, pH 7.4). Protein content was measured using the Pierce BCA protein assay kit 
(Thermo Fisher Scientific) according to the manufacturer’s protocol. 
3.5.2 Evaluation of organelles separation through Western-Blot (WB)  
2 µg of proteins from each fraction was separated onto gradient 4-20% Mini-PROTEAN TGX Precast gel 
(Bio-rad laboratories Inc.) and then transferred onto a Polyvinylidene fluoride membrane (Bio-rad 
laboratories Inc.). The membranes were blocked and cut into strips to be incubated with the primary 


















Cytosol Alfa-Enolase ENO1 47 Rabbit Cell signaling 1:1000 





ATP1A1 100 Rabbit AbCam 1:5000 
ER Calreticulin CARL 55 Rabbit AbCam 1:1000 











LAMP1 100 Rabbit Cell signaling 1:1000 
Nuclear–non 
chromatin 
Fibrillarin FBL 37 Rabbit Cell signaling 1:1000 
Nuclear 
envelope 




4 isoform 1 
(COX 1V) 
COX4I1 17 Rabbit Cell signaling 1:1000 
 
Table 2: List of antibodies for evaluating organelle-specific marker proteins. 
After the incubation with the secondary antibody and addition of the Amersham ECL Prime Western 
Blotting Detection Reagent (GE Healthcare) solution, the membranes were exposed to Fuji films in the 
dark to be used for the evaluation of the separation of the organelles.    
3.5.3 Protein digestion and TMT labelling 
The volume corresponding to 50 µg of proteins from each fraction was transferred into new Eppendorf 
Lo-bind tubes and in-solution digestion was performed following a protocol already described (Paragraph 
3.1.4).  
The tryptic peptides were labelled with TMT isobaric tagging reagents (Thermo Fisher Scientific) according 
to manufacturer’s protocol. Since each TMT kit can be used to tag up to 100 µg of proteins, half of the 
TMT is used for each sample (50 µg of proteins). For this reason, each kit was split in half to be used for 
each replicate (half for the control and half for the treated). The TMT tags were equilibrated at room 
temperature and each tag was dissolved in 82 µL of acetonitrile. After vortexing and centrifuging 2 
minutes at 2000xg, 41 µL of TMT tag solution was added to label each fraction, following the scheme 




Figure 26: Scheme of the TMT labelling tags used for each fraction of the LOPIT-DC workflow.  
The labelling reaction was quenched by adding 8 µL of 5% (w/v) hydroxylamine and incubated for 45 
minutes at room temperature on a shaker. Another quenching step was performed by incubation with 
100 µL of MilliQ water for 30 minutes at room temperature on a shaker. After the TMT labelling, all the 
fractions were pooled together and dried under vacuum.  
3.5.4 Peptide fractionation and LC-MS/MS analysis  
Dried TMT-labelled peptides were resuspended in 1.8 mL of 0.1% TFA (trifluoroacetic acid) and 600 µL of 
this solution was used for the peptide fractionation using the Pierce High pH Reversed-Phase Peptide 
Fractionation Kit (Thermo Fisher Scientific) according to manufacturer’s protocol.  In summary, the 
columns were activated and equilibrated before loading the samples. The peptides were then washed and 
eluted with different solvents, described in Table 3.   











Table 3: Composition of the eluents used for peptide fractionation. 
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In order to decrease the number of the samples for downstream MS analysis (8 fractions of peptides per 
sample, 6 samples in total), the resulting fractions were combined into 4 fractions per sample (Fraction 
1+5; Fraction 2+6; Fraction 3+7; Fraction 4+8).   
All MS runs were performed on an Obritrap Eclipse Tribrid Mass Spectrometer coupled to a Dionex 
Ultimate TM 3000 RSLnano system (Thermo Fisher Scientific). Each of the fractionated samples was 
dissolved in 60 µL of 0.1% formic acid and 2 µL were injected onto a micro precolumn (300-μm x 5 mm, 
C18 PepMap 100, 5-μm particle size, 100-Å pore size, Thermo Fisher Scientific) for the trapping phase (3 
minutes). After the switching of the valve from load to inject, the peptides were separated on a 200 cm 
µPACᵀᴹ column (PharmaFluidics). The nanoLc gradient was set as follows: from 3 to 40% of ACN in water 
+ 0.1% FA at 300 nL/min for 340 minutes. The column was then washed using 95% of ACN + 0.1% FA for 9 
minutes and re-equilibrated for 40 minutes. Total run time was 390 minutes.  
The MS workflow parameters were set as follows using the Method Editor in XCalibur (Thermo Fisher 
Scientific) for the SPS-MS3 acquisition method: Detector type: Orbitrap—Resolution: 120,000—Mass 
range: Normal—Use quadrupole isolation: Yes—Scan range: 400–1,500—RF lens: 30%—AGC target: 
40000—Max inject time: Auto—Microscans: 1—Data type: Profile—Polarity: Positive—Monoisotopic 
peak determination: Peptide—Relax restrictions when too few precursors are found: Yes—Include charge 
state(s): 2–6—Exclude after n times: 1—Exclusion duration (s): 70—Mass tolerance (p.p.m.): Low: 10; 
high: 10— Exclude isotopes: Yes—Perform dependent scan on single charge state per precursor only: 
Yes—Intensity threshold: 5.0e3—Data-dependent mode: Cycle time —Number of scan event types: 1—
Scan event type 1: No condition—MSn level: 2— Isolation mode: Quadrupole—Isolation window (m/z): 
0.7—Activation type: CID —CID collision energy (%): 35—Activation Q: 0.25—Detector type: Ion trap—
Scan range mode: Auto—m/z: Normal—Ion trap scan rate: Rapid—AGC target: 1.0e4— Max inject time 
(ms): 35—Microscans: 1—Data type: Centroid—Mass range: 400–1500—Exclusion mass width: m/z: Low: 
0; high: 0—Reagent: TMT— Precursor priority: Most intense—Scan event type 1: No condition—MSn 
level: 3— Isolation mode: Quadrupole—Isolation window (m/z): 0.7—Activation type: HCD —Collision 
energy (%): 65—Detector type: Orbitrap—Scan range mode: Define—m/z: 100-500—AGC target: 1.0e4— 
Max inject time (ms): 105—Microscans: 1—Data type: Centroid. 
An electrospray voltage of 2.1 kV was applied. The mass spectrometer was operated in positive ion data- 
dependent mode for SPS-MS3 with the real-time (RT) search using the Homo sapiens Swiss proteome 
(downloaded 09/04/2018 as FASTA file). The parameters for the RT-search were: ezyme: trypsin; max 
variable mods: 2; max missed cleavage: 1; Static modification: carbamidomethylation on cysteine and 
TMT-10plex on lysine and peptide N-terminus; variable modifications: oxidation of methionine. 
3.5.5 Data analysis and statistics  
Raw files were processed with Proteome Discoverer version v2.3 (Thermo Fisher Scientific). The acquired 
MS/MS spectra were searched against the Homo sapiens database (canonical and isoform, 42,118 
sequences, downloaded on 04/11/2016) using Proteome Discoverer with Mascot and SequestHF 
algorithms. The research parameters were set as follows: precursor mass tolerance: 10 ppm; fragment 
mass tolerance: 0.6 Da; enzyme used for digestion: Trypsin; maximum missed cleavage: 2; fixed 
modifications: carbamidomethylation of cysteine and TMT10plex tagging of lysine and peptide N terminus 
for TMT labelled samples; dynamic modifications: oxidation of methionine and deamidated asparagine 
and glutamine. Percolator node was used for false discovery rate estimation and only rank 1 peptide 
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identifications of high confidence (FDR < 1%) were accepted. TMT reporter values were assessed through 
Proteome Discoverer v2.3 using the Most Confident Centroid method for peak integration and integration 
tolerance of 20 p.p.m. Reporter ion intensities were adjusted to correct for the isotopic impurities of the 
different TMT reagents (according to the manufacturer specifications for the respective batch number). 
Percolator was used to assess the false discovery rate (FDR) and only high-confidence peptides were 
retained (<1%FDR). Additional data reduction filters were: peptide rank= 1 and ion score >20. 
Quantification at the MS3 level was performed within the Proteome Discoverer workflow using the 
centroid sum method and an integration tolerance of 2 mmu. Isotope impurity correction factors were 
applied. Protein grouping was carried out according to the minimum parsimony principle and the median 
of all sum-normalised PSM ratios belonging to each protein group was calculated as the protein group 
quantitation value. Only proteins with a full reporter ion series were retained.  
The quantified proteins were analyzed using the R Bioconductor [180] packages MSnbase and pRoloc 
following a well-established protocol for LOPIT datasets [181]. 
Briefly, each sample was normalized, the missing values removed and then combined to obtain a map of 
the organelles for each condition. 
A list of 1590 manually-curated marker proteins (defined as proteins known to localize only in one specific 
organelle) was used to pinpoint 11 subcellular localizations: cytosol, ER, proteasome, Golgi, lysosomes, 
mitochondria, nucleus, chromatin, ribosome, peroxisomes and plasma membrane. To predict protein 
localization of the proteins quantified both in the controls and the treated samples, a support vector 
machine (SVM) classifier was used, following a protocol available in literature [181]. To detect proteins 
that changed their localization after the treatment with VX-809, TAGM (t-augmented Gaussian mixture) 







4.1 Creation of the ion library for CF research 
As mentioned in the introduction, for SWATH proteomics it is very important to setup a reliable ion library 
specifically dedicated and optimized for the proteome under investigation. This ensures the best accuracy 
and specificity in protein quantification. Both immortalized (CFBE41o-) and BE primary cells were then 
analyzed to create an ion library highly specific for CF research. During sample preparation, two kinds of 
fractionation methods were applied in order to deepen the coverage of the proteome.  
The ion library (IL) deriving from the analysis of CFBE41o- reports assays for 5627 proteins and it only 
reports unique and unmodified peptides (peptides not shared, and not carrying PTMs other than cysteine 
carbamidomethylation and oxidation on methionines). For human samples, the PanHuman IL is the most 
complete ion library available so far and it derives from the analysis of different types of cells and tissues 
[150]. Despite its outstanding quality, the PanHuman IL lacks assays for several proteins essential to study 
CF (such as proteins involved in CFTR trafficking and CFTR itself). For this reason, we compared our new 
IL with the PH one in order to detect those proteins highly specific for CF that are not present in the 
PanHuman IL.  
After comparing the CFBE41o- ion library and the PH, we identified 124 proteins that are specific for the 
human bronchial epithelium. Among these proteins, CFTR is present, together with some of its known 
interactors, such as RNF185, demonstrating the high specificity of this new ion library to study CF.  
The IL of the BE primary cells, created exactly as the CFBE41o- cells one, reports assays for 3805 proteins.  
A comparison of the CF-specific ion libraries with the PH one was then performed, in order to understand 
the number of proteins to be added. The results of this comparison are shown in Figure 27. 
 
Figure 27: Overlap analysis comparing the proteins present in the PanHuman, the BE and CFBE41o- cells libraries. Figure taken 
from Braccia C., SWATH label-free proteomics for cystic fibrosis research [151]. 
The assays corresponding to CF-specific proteins (124 and 77 for CFBE41o- and BE primary cells, 
respectively) were manually added to the PanHuman ion library, thus producing a new and improved ion 
library, now reporting assays for 14683 proteins. These proteins include CFTR and other proteins very 
relevant for CF research, like RNF185, RNF5, DLG4 and STX1A. These molecules are known CFTR 




Figure 28: CFTR interactors among the 124 proteins identified only in the CFBE41o-. Figure taken from Braccia C., SWATH label-





4.2 Proteomics profiling of BE primary cells (CF vs non-CF) 
To demonstrate the efficacy of the new ion library, a quantitative proteomics analysis was performed to 
monitor the changes in protein expression induced by CF pathology on BE cells directly obtained from CF 
subjects and non-CF controls, beyond the intrinsic inter-individual variability. To perform this analysis, the 
BE cells described above (Paragraph 3.1.6) were used: the proteome of four primary cultures of BE cells 
obtained from four CF patients was compared to the proteome of four non-CF subjects, used as control.  
As a test, SWATH data were then acquired and searched against different ion libraries. As shown in Table 
4, an increase in the number of quantified proteins was achieved with the use of the modified PH ion 
library.  
 
Table 4: Number of quantified proteins from total BE lysates using different ion libraries. For each dataset, the number of 
proteins significantly altered by CF is shown (results from unpaired, two-tails t-test CF vs non-CF, 4 samples each). 
By using the proteins quantified with the new version of the PH IL, a t-test (un-paired, two-tails t-test CF 
vs non-CF, 4 samples each) was then performed and 154 proteins significantly (p. value < 0.05) 
dysregulated by CF pathology (94 upregulated and 60 downregulated) were identified. As expected, given 
the low natural levels of expression, CFTR was not quantified in the primary BE dataset. 
The interaction maps created with STRING (Paragraph 3.1.9) show that, among the proteins significantly 






Figure 29: Detail of the CFTR cluster from the STRING analysis of the significantly up-regulated proteins by CF in BE cells. Since 
CFTR was not quantified, it was manually added to the dataset in STRING. 
Proteasome subunit alpha 4 (PMSA4) plays a key role in the ATP-dependent degradation of ubiquitinated 
proteins [182], and in the REACTOME pathways database [159] it is directly associated to the degradation 
of ubiquitinated CFTR (pathway: R-HSA-5678895). Tight junction protein 1 (TJP1) is a known direct 
interactor of CFTR [106] and based on REACTOME, both proteins are involved in membrane trafficking 
(pathway: R-HSA-199991). 
Among the up-regulated proteins detected by this experiment, there is a cluster of mitochondrial 
ribosomal proteins (MRPS22, MRPS15, MRPL44, MRPL40 and RPL37A) and proteins belonging to 
coatomer complex [183], known to regulate the Golgi-endoplasmic reticulum (ER) protein trafficking [184] 
(COPB1, COPE, ARF5 and GBF1), as shown in Figure 30.   
 
Figure 30: Two clusters of proteins (detected as up-regulated by CF) involved in protein trafficking. 




Figure 31: Detail of the CFTR cluster from the STRING analysis of the significantly down-regulated proteins by CF in BE dataset. 
Since CFTR was not quantified, it was manually added to the dataset in STRING. 
E3 ubiquitin-protein ligase CHIP (STUB1), which has a crucial role in CFTR maturation [185], is 
downregulated in the dataset. As shown in Figure 31, STUB1 protein interacts with other two proteins 
that are downregulated in the BE of CF patients: anaphase-promoting complex subunit 1 (ANAPC1) and 
the multiubiquitin receptor RAD23 [186]. Together with STUB1 protein, ANAPC1 and RAD23 proteins are 
involved in the ubiquitin-mediated proteolysis pathway reported in the KEGG database [187]. 
The downregulation of STUB1 protein is apparently in contrast with previous literature (although obtained 
on totally different in vitro cell models, such as HEK293), where the decrease of CFTR is normally 
associated with CHIP upregulation [185].This event might, thus, be specific for BE and warrants further 
studies or larger patients cohorts.  
Two proteins correlated to CFTR activity (PP1CA and PPP1R12C, two type-1 protein phosphatases) were 
detected among the downregulated proteins. While type-2 protein phosphatases are known to be 
associated with CFTR [188], type-1 phosphatase has more recently been demonstrated to regulate anion 
exchange in synergy with CFTR [189]. Very recently, S-nitrosation of type-1 phosphatase has been proved 
to regulate ciliary activity [190] and in-situ production of nitrosothiols (by S-nitrosoglutathione reductase 




4.3 Proteomics profiling of CFBE41o- after gene silencing 
After demonstrating the efficiency of our new IL in detecting changes of proteins highly specific for CF in 
bronchial epithelium primary cells, we used our new tool also to quantify the proteins of CFBE41o- cell 
lysates in order to detect those proteins changing their expression after the gene silencing of four proteins 
(FAU, LRRC, PHF, RNF5, Paragraph 3.3.1).    
The LC-MS/MS analysis of the CFBE41o- cells after the gene silencing of four proteins (Paragraph 3.3) 
allowed the quantification of 4010 proteins in all the samples. The unsupervised multivariate analysis was 
performed and the resulting PCA score plot is showed in Figure 32. 
 
Figure 32: PCA score plot of all the samples after the gene silencing of the four proteins described above (Paragraph 3.3.1). For 
the multivariate analysis, the normalized data were pre-processed with logarithm weighting and Pareto scaling (Paragraph 3.3.3). 
From the PCA score plot, it is possible to notice that none of the five groups is clearly separated from all 
the other groups (the distance between samples within the same group is higher than the distance of 
different groups) and that the total variance expressed by both PC1 and PC2 is 12.1%. (PC1=6.2% and 
PC2=5.9%). This suggests that the gene silencing performed does not have a huge impact on total protein 
expression. 
To select the putative new targets, binary comparisons (Paragraph 3.3.4) were then performed to detect 
the significantly altered proteins by each gene silencing. Two strategies were followed to find new 
potential targets:  
 Protein-centric approach 





4.3.1 Protein-centric approach  
After the binary comparisons, the proteins significantly altered in association with the silencing of all the 
genes were identified. Figure 33 shows the Venn diagram of the number of proteins significantly altered 
by siRNA.  
 
Figure 33: Venn diagram of the number of the proteins that were significantly dysregulated by the gene silencing. Panel A shows 
the number for the up-regulated proteins and Panel B shows the number of the down-regulated proteins. Red circles highlight 
the number of the proteins significantly altered in common among all the gene silencing experiments (7 and 11 for up- and 
down-regulated respectively). 
Among the seven proteins significantly up-regulated by all the groups, there is CFTR, whose levels of 
expression are shown in Figure 34. This result shows that the ion library (Paragraph 3.1) is highly specific 
for CF research and that the gene maneuvers worked as expected and a significant CFTR rescue is 































Figure 34: Histogram graph to compare the expression of CFTR in each group. The p-values derive from a t-test (un-paired, 2 
tails t-test; N=4 for DMSO and N=5 for siRNAs) are shown each group in comparison to the control (DMSO). 









Table 5: List of the seven significantly up-regulated proteins: for each protein, described by both gene and protein name, a brief 
description of its function is shown. 
From this list of proteins, four proteins were selected as possible direct effectors for CFTR functional 
rescue: 
 GTF2F1 (General transcription factor IIF subunit 1), which is a general transcription factor acting 
on several genes with functions not completely known [192]. 
 CDV3 (Protein CDV3 homolog), which may have a role in cell proliferation [193].  
 EHD1 (EH domain-containing protein 1), able to bind both ATP and membrane, which acts in early 
endocytic membrane fusion and membrane trafficking of recycling endosomes [194]. 
 HSP90B1 (Endoplasmin), a molecular chaperone directly involved in CFTR processing and folding 
[106].   
Table 6 reports the proteins significantly down-regulated upon gene suppression of all the four proteins.  
 
Gene name Protein name Protein function 
HSP90B1 Endoplasmin 
Molecular chaperone that functions in the 
processing and transport of secreted proteins 
CDV3 Protein CDV3 homolog Role in cell proliferation 
SCO1 
Protein SCO1 homolog, 
mitochondrial 
Copper metallochaperone essential for the 




ATP- and membrane-binding protein that acts in 
early endocytic membrane fusion and 




Catalyzes the irreversible transamination of the 
L-tryptophan metabolite, L-kynurenine to form 
kynurenic acid (KA). Plays a key role in amino 
acid metabolism and in metabolite exchange 
between mitochondria and cytosol. Facilitates 
cellular uptake of long-chain free fatty acids 
GTF2F1 
General transcription factor IIF 
subunit 1 
General transcription initiation factor that binds 
to RNA polymerase II, promoting the 
transcription elongation 
CFTR 
Cystic fibrosis transmembrane 
conductance regulator 




Gene name Protein name Function 
CBS Cystathionine beta-
synthase 




Oxidoreductase involved in several pathways 
MAPKP13 Mitogen-activated 
protein kinase 13 
Serine-threonine kinase involved in the response to 
osmotic stress 
CDK1 Cyclin-dependent kinase 
1 




Catalyzes the cross-linking of proteins and the 
conjugation of polyamines to proteins. 
MAL2 Protein MAL2 Member of the machinery of polarized transport. 
UHRF1 E3 ubiquitin-protein 
ligase UHRF1 
Multidomain protein that acts as a key epigenetic 
regulator (by bridging DNA methylation and chromatin 
modification) and as E3 ubiquitin-protein ligase. It is still 
unclear how the two activities are related. 
SMARCE1 SWI/SNF-related matrix-
associated actin-
dependent regulator of 
chromatin subfamily E 
member 1 
Involved in transcriptional activation and repression of 




Thiol-specific peroxidase that plays a role in cell 
protection against oxidative stress by detoxifying 
peroxides and as a sensor of hydrogen peroxide-
mediated signalling events. 
PCBP2 Poly(rC)-binding protein 
2 
Nucleic acid-binding protein. Negatively regulates 
cellular antiviral responses and is involved in 
proteasome-mediated protein catabolic process. 
FN1 Fibronectin Fibronectins bind cell surfaces and various compounds 
including chaperones 
 
Table 6: List of the eleven proteins significantly down-regulated by all the gene silencing: for each protein, described by both 
gene and protein name, a brief description of its function is shown. 
From the 11 down-regulated proteins in association with all the siRNA silencing, six proteins were selected 
as putative direct effectors for CFTR functional rescue: 
 SMARCE1 (SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily 
E member 1), which is involved in transcriptional activation and repression of select genes by 
chromatin remodelling [195].  
 PCBP2 (Poly(rC)-binding protein 2), which can be involved in ubiquitin ligase activity [195].  
 CBS (Cystathionine beta-synthase), which is an adapter of the E3 ubiquitin ligase [196].  
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 MAL2 (Protein MAL2), which is a member of the machinery of polarized transport; required for 
the indirect transcytotic route [197].  
 UHRF1 (E3 ubiquitin-protein ligase UHRF1), a ubiquitin ligase known to be involved in DNA 
methylation and chromatin modification [198] but it can be involved also in CFTR degradation.  
 MAPK13 (Mitogen-activated protein kinase 13), a serine/threonine kinase which plays an 
important role in the cascades of cellular responses evoked by extracellular stimuli such as pro-
inflammatory cytokines or physical stress. Its inhibition can alter airway mucus production [199]. 
From this experiment, a total of ten proteins were selected as putative direct effectors of CFTR functional 
rescue. In order to understand whether the selected proteins are involved in CFTR functional rescue or if 
their dysregulation is a side effect of the gene maneuvers, CFTR activity was measured after the gene 
suppression of the selected proteins, through the YFP-based assay (Paragraph 3.3.2). The suppression of 
proteins down-regulated in the first experiment should, in principle, favor CFTR, while suppression of the 
up-regulated proteins should play against CFTR rescue caused by FAU gene silencing.  
For this reason, the expression of the ten selected proteins was suppressed either alone or in combination 
with FAU in CFBE41o- cells. Figure 35 shows the results of the YFP-based assay to evaluate CFTR activity 
in different conditions. To obtain a more robust outcome, 3 individual cell preparations, each with 5 
individual biological replicates, were prepared for each condition.  
 
Figure 35: CFTR rescue following silencing of the 10 selected proteins tested each independently (A) or in combination with FAU 
suppression (B). Three independent cell preparations, each with 5 biological replicates of CFBE41o- cells were used; genes 
silenced with pools of 3 siRNA, 50 nM final concentration. Statistical significance was assessed by parametric ANOVA, followed 
by Dunnett’st multiple post-hoc test. **=p<0.01 versus control (cells transfected with Non-Targeting siRNA Pool). 
From panel A, it is clear that two proteins (CDV3 and UHRF1), when silenced, trigger an increase in CFTR 
activity in comparison with the control. Since CDV3 was up-regulated by the first gene silencing, the 
increase in CFTR activity after its suppression shows that CDV3 negatively affects CFTR rescue and 
72 
 
processing. Panel B shows that the silencing of GTF2F1 protein triggers a significant down-regulation of 
CFTR activity when combined with the gene silencing of FAU. 
To address this point, GTF2F1 silencing was performed in combination with either FAU or RNF5 silencing. 
As shown in Figure 36, FAU silencing is almost ineffective in rescuing CFTR when performed together with 
GTF2F1 silencing. On the other hand, CFTR rescue following RNF5 silencing is not impaired when GTF2F1 
is absent.  
 
 
Figure 36: CFTR rescue following GTF2F1 silencing together with either FAU or RNF5 silencing. Five independent cell 
preparations, each with 5 biological replicates, genes silenced with pools of 3 siRNA, 50 nM final concentration were tested. 
Statistical significance was assessed by parametric ANOVA, followed by Dunnett’s multiple post-hoc test. **=p < 0.01 versus 
control (cells transfected with Non-Targeting siRNA Pool). 
These results suggested that CFTR rescue following FAU silencing could somehow be mediated by GTF2F1. 
These data could be very helpful in understanding the mechanism of action of FAU on CFTR rescue, which 
is still unknown. Further experiments are currently ongoing to specifically address this point.   
4.3.2 Pathway-centric approach  
In order to find other new putative targets for CF treatment, we then focused on the biological pathways 
– rather than proteins – altered in association with the silencing maneuvers. We investigated these 
pathways by performing gene enrichment search, by using the Reactome database (Paragraph 3.2.4). 
Reactome was interrogated with the dysregulated proteins from each of the groups and the resulting 
pathway identifiers were listed and filtered (only pathways identified by at least two peptides and showing 
the value of FDR <0.02 were retained). With these settings, four biological pathways significantly 










Pathway Name FDR 
R-HSA-70614 Amino acid synthesis and interconversion (transamination) 0,19 
R-HSA-75035 Chk1/Chk2(Cds1) mediated inactivation of Cyclin B: Cdk1 
complex 
0,08 
R-HSA-379716 Cytosolic tRNA aminoacylation 0,15 
R-HSA-5628897 TP53 Regulates Metabolic Genes 0,10 
 
Table 7: Biological pathways significantly downregulated following CFTR rescuing maneuvers. Each pathway is described with its 
pathway identifier, name and FDR (probability corrected for multiple comparisons) value, provided by Reactome databases 
[159]. 
Eleven proteins, known as being among the key regulators of these pathways, were selected for further 
investigation, by manually scrutinizing all the pathways data available. The list of the selected proteins is 
showed in  
Table 8.  
Gene name Protein name Function 
YWHAZ 14-3-3 protein zeta/delta Adapter protein implicated in the regulation of a 
large spectrum of both general and specialized 
signaling pathways. 
YWHAG 14-3-3 protein gamma Adapter protein implicated in the regulation of a 
large spectrum of both general and specialized 
signaling pathways. 
GLS Glutaminase kidney isoform, 
mitochondrial 
Catalyzes the first reaction in the primary 
pathway for the renal catabolism of glutamine. 
Plays a role in maintaining acid-base 
homeostasis. Regulates the levels of the 
neurotransmitter glutamate. 
PRDX2 Peroxiredoxin-2 Plays a role in cell protection against oxidative 
stress by detoxifying peroxides and as sensor of 
hydrogen peroxide-mediated signaling events. 
Might participate in the signaling cascades of 
growth factors and tumor necrosis factor-alpha.  
PRDX5 Peroxiredoxin-5 Plays a role in cell protection against oxidative 
stress by detoxifying peroxides and as sensor of 
hydrogen peroxide-mediated signaling events. 
LAMTOR1 Ragulator complex protein 
LAMTOR1 
Involved in amino acid sensing and activation of 
mTORC1, a signaling complex promoting cell 
growth in response to growth factors, energy 
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levels, and amino acids. Also required for late 
endosomes/lysosomes biogenesis. May be 
involved in cholesterol homeostasis. 
LAMTOR2 Ragulator complex protein 
LAMTOR2 
Involved in amino acid sensing and activation of 
mTORC1, a signaling complex promoting cell 
growth in response to growth factors, energy 
levels, and amino acids.  
SERINC3 Serine incorporator 3 Restriction factor required to restrict infectivity 
of lentiviruses: acts by inhibiting an early step of 
viral infection. Impairs the penetration of the 
viral particle into the cytoplasm. 
AIMP1 Aminoacyl tRNA synthase 
complex-interacting 
multifunctional protein 1 
Non-catalytic component of the multisynthase 
complex. Stimulates the catalytic activity of 
cytoplasmic arginyl-tRNA synthase. Possesses 
inflammatory cytokine activity. Negatively 
regulates TGF-beta signaling. Involved in glucose 
homeostasis. Promotes dermal fibroblast 
proliferation. Regulates KDELR1-mediated 
retention of HSP90B1/gp96 in the endoplasmic 
reticulum. Plays a role in angiogenesis. Induces 
maturation of dendritic cells and monocyte cell 
adhesion. Modulates endothelial cell responses. 
AIMP2 Aminoacyl tRNA synthase 
complex-interacting 
multifunctional protein 2 
Required for assembly and stability of the 
aminoacyl-tRNA synthase complex. Mediates 
ubiquitination and degradation of FUBP1. Blocks 
MDM2-mediated ubiquitination and 
degradation of p53/TP53. Functions as a pro-
apoptotic factor. 
PPP2R5D Serine/threonine-protein 
phosphatase 2A 56 kDa 
regulatory subunit delta 
isoform 
The B regulatory subunit might modulate 
substrate selectivity and catalytic activity, and 
also might direct the localization of the catalytic 
enzyme to a particular subcellular compartment. 
 
Table 8: List of the eleven proteins, which are key regulators of the pathways significantly altered by all the four gene silencing. 
Each protein is described by gene name, protein name and a brief description of its function. 
YFP-based assay (Paragraph 3.3.2) was performed to measure CFTR activity after the gene silencing of 




Figure 37: Preliminary experiment (one cell preparation with 5 biological replicates) showing CFTR rescue following silencing of 
11 proteins selected with the pathway-centric approach. 
From these results, two proteins (SERINC3 and AIMP1), when silenced, appear to trigger CFTR functional 
rescue.  
The YFP-based assay was performed also to measure CFTR activity after the gene silencing of each of these 
proteins either independently or in combination with VX-809 treatment. The results of this assay are 




Figure 38: Results of the YFP-based assay to measure CFTR rescue following silencing of 11 proteins selected with the pathway-
centric approach either independently or in combination with VX-809 treatment (1 µM). These are results of four independent 
cell preparations with 5 biological replicates, genes silenced with pools of 4 siRNA, 100 nM final concentration. Black line 
corresponds to the corresponding control (activity on cells transfected with non targeting siRNA in A, and activity in cells after 
treatment with VX-809 1µM in B). Statistical significance was assessed by parametric ANOVA, followed by Dunnett’s multiple 
post-hoc test. **=p < 0.01 versus control (cells transfected with Non-Targeting siRNA Pool). 
These results show that two proteins (AIMP1 and PRDX2) trigger an increase in CFTR activity (about 20%) 
in combination with VX-809 treatment. Interestingly, the silencing of PRDX5, a protein belonging to the 
same protein family of PRDX2, does not trigger CFTR rescue.  
Since, in CF research, it is believed that the restoration of 5-10% of CFTR activity may be of substantial 
therapeutic value [200], these preliminary results are quite promising and thus worth of further 
investigations. 
4.3.3 Selection of putative targets and treatment with modulators 
The aim of this experiment was to identify new potential targets for CF. To reach this aim, we performed 
a proteomic profiling of CFBE41o- cells following the silencing of four proteins known to trigger CFTR 
rescue. We then focused on the identification of changes associated with the genetic maneuvers both at 
protein and pathway levels. After an extensive literature search (Paragraph 3.3.4), 27 proteins (listed in 
Table 9) were selected as new potential targets.  
Target Name Pathway 
LARS Leucyl-tRNA synthetase aminoacyl-tRNA synthetase 
UHRF1 E3 ubiquitin-protein ligase UHRF1 / 
HSP90B1 Endoplasmin / 




CCNB1 G2/mitotic-specific cyclin-B1 Chk1/Chk2(Cds1) mediated inactivation of Cyclin 
B:Cdk1 complex 
YWHAG 14-3-3 protein gamma Chk1/Chk2(Cds1) mediated inactivation of Cyclin 
B:Cdk1 complex 
YWHAZ 14-3-3 protein zeta Chk1/Chk2(Cds1) mediated inactivation of Cyclin 
B:Cdk1 complex 
CDK1 Cyclin-dependent kinase 1 Chk1/Chk2(Cds1) mediated inactivation of Cyclin 
B:Cdk1 complex 
PRKAG1 5'-AMP-activated protein kinase subunit 
gamma-1 
TP53 Regulates Metabolic Genes 
PRKAA1 5'-AMP-activated protein kinase catalytic 
subunit alpha-1 
TP53 Regulates Metabolic Genes 
PRKAA2 5'-AMP-activated protein kinase catalytic 
subunit alpha-2 
TP53 Regulates Metabolic Genes 
PRKAB1 5'-AMP-activated protein kinase subunit 
beta-1 
TP53 Regulates Metabolic Genes 
YWHAG 14-3-3 protein gamma TP53 Regulates Metabolic Genes 
YWHAE 14-3-3 protein epsilon Chk1/Chk2(Cds1) mediated inactivation of Cyclin 
B:Cdk1 complex 
SFN 14-3-3 protein sigma Chk1/Chk2(Cds1) mediated inactivation of Cyclin 
B:Cdk1 complex 
CDC25C Dual specificity phosphatase Cdc25C Chk1/Chk2(Cds1) mediated inactivation of Cyclin 
B:Cdk1 complex 
CHEK2 Serine/threonine-protein kinase Chk2 Chk1/Chk2(Cds1) mediated inactivation of Cyclin 
B:Cdk1 complex 
KARS Lysyl-tRNA synthetase aminoacyl-tRNA synthetase 
LARS Leucyl-tRNA synthetase aminoacyl-tRNA synthetase 





PROTEIN COMPLEX GROUP: AMP-activated 
protein kinase, AMPK 
TP53 Regulates Metabolic Genes 
TNX Thioredoxin TP53 Regulates Metabolic Genes 
MDM4-TP53-MDM2 PROTEIN-PROTEIN INTERACTION TP53 Regulates Metabolic Genes 
YWHAE 14-3-3 protein epsilon TP53 Regulates Metabolic Genes 
HSP90 Endoplasmin / 
UHRF1 E3 ubiquitin-protein ligase UHRF1 / 
PRDX2 Peroxiredoxin-2 TP53 Regulates Metabolic Genes 
 
Table 9: List of putative targets. For each of them, one or more modulators were tested of CFBE41o- cells. 
As already described above (Paragraph 3.3.4), we then used several databases to find compounds able to 
chemically modulate these pathways. The selection of the chemical entities to test was mainly performed 
based on the following criteria:  
a) Biological activity: the modulator must efficiently act on its target(s).  
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b) LogP: this parameter is the index of the lipophilicity of a molecule and it was considered in order 
to select modulators that were soluble in the medium of the CFBE41o- cells. 
c) Safety: the modulators should have no reported adverse effects.  
d) Availability: the modulators to be tested must be commercially available.  
A total of 45 modulators for the targets reported in Table 10 were tested at concentrations ranging from 
0.04 µM to 10 µM (based on their solubility and activity data) on CFBE41o- cells, and CFTR rescue was 
assessed with YFP-based assay.    
 
N Name Target Action 














4 Withaferin A HSP90 Inhibition 
5 Pifithrin-µ TP53 Inhibition 
6 Brotezomib UHRF1 Inhibition 
7 H-89 | H-89 Chloride CHEK2 Inhibition 
8 Seliciclib CCNB1 Inhibition 
9 (-)-Gambogic acid TNX Inhibition 
10 1-(1H-Indol-3-ylmethyl)proline CDC25C Inhibition 































18 Alpha-Amyrin YWHAE Inhibition 
19 NSC-114945 | Oleanolic Acid Glutaryl Hemi Ester YWHAE Inhibition 
20 (2S)-4-Methyl-1,2-pentanediamine LARS Inhibition 














25 QUINOLYLUREA CDC25C Inhibition 



















31 clofibrate TP53 Inhibition 
32 7-Azaindole | 1H-Pyrrolo[2,3-B]Pyridine CHEK2 Inhibition 
33 L-(+)-Leucinol LARS Inhibition 
34 5-Acetyluracil UHRF1 Inhibition 
35 Methyl mesylate TP53 Inhibition 
36 Azacitidine UHRF1 Inhibition 
37 (4S)-4-(2-methylpropyl)-1,3-oxazolidin-2-one LARS Inhibition 
38 (3S)-5-methylhexane-1,3-diamine LARS Inhibition 
39 2-(2-methylpropyl)-1H-imidazole LARS Inhibition 
40 (3S)-3-Amino-5-methyl-1-hexanol LARS Inhibition 





43 Novobiocin HSP90 Inhibition 
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Table 10: List of modulators of putative targets tested on CFBE41o- cells. 
The corresponding results of the YFP-based assay to measure CFTR rescue following the treatment with 








Figure 39 shows that only the compound 23, trigger a CFTR rescue that is comparable with the rescue of 
CFTR following VX-809 treatment. For this reason, only the compound 23 was tested on the BE primary 
cells derived from a patient homozygous for F508del-CFTR either alone or in combination with the 
corrector VX-445. The corresponding results of the short-circuit current recordings in Ussing chamber 
following the treatments are showed in Figure 40.  
For this experiment, bronchial epithelia differentiated under air-liquid condition were treated for 24 hours 
by adding the compounds to the basolateral medium.  The following day, the epithelia were mounted in 
a perfusion chamber to measure short-circuit current. After inhibition of the epithelial sodium channel 
(ENaC) with amiloride (10 µM), cells were stimulated with the membrane permeable cAMP analogue CPT-
cAMP (100 µM) plus VX-770 (1 µM) to maximally activate F508del-CFTR. Then, we inhibited CFTR channel 
by adding the CFTR inhibitor-172 (10 µM).  The amplitude of the current drop caused by inh-172 was taken 
as an estimate of total CFTR activity in each epithelium.  
In epithelia treated for 24 hours with vehicle alone (DMSO) the total CFTR activity is very low (Figure 40). 
Treatment with compound 23 caused no increase in CFTR-mediated current (Figure 40). Interestingly, 
epithelia that were treated with VX-445 for 24h displayed remarkably augmented chloride secretion, with 
a 4-to-5-fold increase in CFTR total current (Figure 40). However, no further increase was observed when 
epithelia were treated with VX-445 and compound 23 (Figure 40). 
 
Figure 40: Representative traces and summary of results obtained from short-circuit current recordings on F508del/F508del 
bronchial epithelial cells. Data reported as mean ± SD of the amplitude of the current blocked by inh-172 (10 µM) in epithelia 
treated with the indicated compounds. *P < 0.05 and **P < 0.01 versus control [analysis of variance (ANOVA) with Dunnett’st’s 
post hoc test]. 
Further experiments on other compounds selected are still on going. Compound 21 will also soon be 
tested on primary cells.  
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4.4 Lipidomics profiling of CFBE41o- after incubation with drugs  
The importance of membrane lipids in the physiology and trafficking of CFTR was recently investigated:  
cholesterol and ceramides have a role in the formation of CFTR clusters at the plasma membrane [201], 
[202]; phosphatidylserines help in stabilizing CFTR at the plasma membrane [203]. Another very recent 
study shows the significant role of cholesterol in CFTR activity [115]. Other important players in the 
stabilization of CFTR at the PM are the flippases [204], enzymes that regulate the phospholipids 
movement across the membranes of the cells.   
Moreover, recent studies points at a very significant role of the cell lipidome in the mechanism of action 
of CF drugs:  
 A positive impact of pharmacological modulation on the sphingolipids signaling pathway in CF 
pathology has been proposed [205], [206].  
 On the other hand, a negative effect on CFTR half-life at the plasma membrane has been 
associated with chronic co-administration of the potentiator ivacaftor (VX-770) and the corrector 
lumacaftor (VX-809) [207], [208].  
Although all these studies gave an important contribution in elucidating the role of some lipids in CF, an 
untargeted lipidomics profile of the bronchial epithelial cells has not previously been performed. The aim 
of this experiment was to investigate the lipidome profile of the F508del-CFTR expressing cells following 
successful CFTR pharmacological rescue strategies. We hypothesized that the pharmacological rescue of 
mutant CFTR could be associated with changes in lipidome profile of CFBE41o- cells. All the data generated 
by the lipidomics experiment on the CFBE41o- (Paragraph 3.4) were analyzed by multivariate data analysis 
tools like PCA and PLS-DA to identify changes in the global lipidomic profiles. 
For this experiment, several groups were analyzed:  
 The treated groups: cells were treated with different CF drugs (the corrector VX-809, the 
potentiator VX-770, the combination of VX-809 and VX-770 and the triple combination of VX-
661/VX-445/VX-770). 
 The control group: cells were treated with DMSO. 
 The QCs: quality control samples resulting from the pooling of all the samples. 
 The blank groups: both procedural blanks and acquisition blanks for LC-MS/MS runs.  
The PCA score plot revealed not only a clear separation between the groups (the QCs, the treated samples 
and the controls) and blank runs (Figure 41) but also differences between the five experimental groups, 




Figure 41: PCA score plot of all the features observed from all the experimental groups. Picture taken from Liessi N., Distinctive 
lipid signatures of bronchial epithelial cells associated with cystic fibrosis drugs, including Trikafta [149]. 
 
Figure 42: PCA score plots of all the features observed from all the experimental groups, different PCs were selected and 
indicated in the plots. Pictures taken from Liessi N., Distinctive lipid signatures of bronchial epithelial cells associated with cystic 
fibrosis drugs, including Trikafta [149]. 
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Another PCA score plot revealed that the group treated with the combination VX-809-VX-770 is well-
separated from the groups treated with the molecules separately (shown in Figure 43).  
 














The separation of all the groups was revealed by the PLS-DA plot, shown in Figure 44.  
 
Figure 44: PLS-DA score plot of the lipidomics analysis of CFBE41o- after treatment with drugs. DSMO group represents the 
control, where the cells were treated only with the vehicle. Blank and QC groups are omitted for clarity. Picture taken from Liessi 
N., Distinctive lipid signatures of bronchial epithelial cells associated with cystic fibrosis drugs, including Trikafta [149]. 
The leave one out cross-validation of PLS-DA analysis (Figure 45), demonstrated that the PLS-DA model 





Figure 45: Results of leave-one-out cross validation of the PLS-DA model. Positive Q2 values (0.6 and 0.8 for 1 and 2 principal 
component respectively) indicate that the model is not overfitted. 
The supervised analysis, accounting for 26% of the total PC variability observed in the dataset, showed 
that:  
 The differences among the experimental groups exceeded the observed variability among the 
different biological replicates, represented by the spreading of the dots within the same group. 
 Each treatment caused peculiar changes into the cell lipidome, resulting in a clear separation of 
all the groups. Based on VIP scores, 75 features (provisionally identified with their RTs and m/z 
values) were selected as those contributing the most to the groups’ separation. Based on these 
signals, a clusterization analysis was performed and the resulting heatmap (Figure 46) shows that 
the samples naturally cluster into the five experimental groups. Using the LIPIDMAPS database 




Figure 46: Heatmap resulting from the clustering analysis of the CFBE41o- lipidomics dataset. This heatmap was created using 
the top 75 PLS-DA VIP features. Picture taken from Liessi N., Distinctive lipid signatures of bronchial epithelial cells associated 
with cystic fibrosis drugs, including Trikafta [149]. 
 
Moreover, a pattern correlation analysis (Figure 47) revealed the presence of two major clusters of 
activated lipid pathways: the glycerophospholipid and the sphingolipid metabolisms. These results 




Figure 47: Patterns of correlation among the 48 lipids. Two main clusters of lipids were observed (labelled 1 and 2) Picture taken 
from Liessi N., Distinctive lipid signatures of bronchial epithelial cells associated with cystic fibrosis drugs, including Trikafta 
[149]. 
Besides the multivariate data analysis, where the results of a simultaneous comparison of all the tested 
groups were analyzed all at once, binary comparisons were also performed to detect distinctive changes 












4.4.1 Role of VX-770  
The Venn diagram in Figure 48 highlights the overlap of the lipids significantly altered in all the conditions 
involving the use of VX-770.  
 
 Figure 48: Venn diagram reporting significantly altered lipids (compared to control, FDR 0.05, FC>1.5) from the treatments 
involving VX-770. Picture taken from Liessi N., Distinctive lipid signatures of bronchial epithelial cells associated with cystic 
fibrosis drugs, including Trikafta [149]. 
The treatment with Trikafta (VX-445/VX-661/VX-770) has the biggest impact on the lipidome profile of 
CFBE41o- cells, with 39 lipids altered only by this treatment. At the intersection of all the groups, 8 lipids 
are altered (all down-regulated compared to the control groups) by all the treatments involving VX-770, 




Table 11: Summary of the lipids dysregulated by each treatment involving VX-770. The red lipids are in common among all the 
treatments involving VX-770. Figure adapted from Liessi N., Distinctive lipid signatures of bronchial epithelial cells associated 
with cystic fibrosis drugs, including Trikafta [149]. 
As shown in Table 11, among the 8 down-regulated lipids, the phosphatidylcholines, lipids which are 
among the major components of cell membranes [209], are present. These molecules have a  huge impact 
on the mechanical and biophysical properties of the membranes [210]. It was already demonstrated that 
changes in the metabolism of this class of lipids are linked to the altered membrane recycling in CF [211]. 
Moreover, these lipids are one of the major components of BAL (Broncho-Alveolar Lavage) fluid in CF 
patients [212]. These results are consistent with other studies already conducted by Bear’s group, 
demonstrating that VX-770 increases membrane fluidity, by interacting with membrane lipid structures 
[213]. Another study [214] demonstrated that VX-770 restores the secretion of the phosphatidylcholine 
lipids, which is mediated by the ABCB4 membrane transporter. This increased secretion can cause the 
decrease of the individual phosphatidylcholine lipids detected in this lipid experiment.  
The observed downregulation of ceramide is also intriguing, since ceramides are known to accumulate in 
CF epithelial cells, causing inflammation and cell death [215]. Moreover, ceramides were associated with 







4.4.2 Focus on the effect of the triple combination (Kaftrio)  
Since Kaftrio is the latest drug approved for CF therapy [49], its global effects on cell lipidome have not 
been investigated yet. As shown in Table 11, Kaftrio has the major effect on CFBE41o- cells lipidome, 
causing the upregulation of 22 lipids and the downregulation of 37 lipids. Figure 49 shows that the control 
and the treated (with Kaftrio) group are already clearly separated on the PCA score plot.  
 
Figure 49: PCA score plot of the control and triple combination (VX-661/VX-445/VX-770, Trikafta) comparison showing a clear 
separation of the groups in the PC1 and PC2. Figure adapted from Liessi N., Distinctive lipid signatures of bronchial epithelial 
cells associated with cystic fibrosis drugs, including Trikafta [149]. 
From this untargeted approach, ceramides resulted the most altered lipids (downregulated) by this 
treatment. To confirm these results, a targeted analysis (Paragraph 3.4.4) was performed to specifically 
measure the levels of six ceramides in all the groups. These six lipids, [Cer(d18:1/16:0), Cer(d18:1/18:0), 
Cer(d18:1/20:0), Cer(d18:1/22:0), Cer(d18:1/24:1), Cer(d18:1/24:0)], are among the most abundant 
ceramides in mammalian tissues [217].  
Figure 50 shows the results of the targeted analysis: only the treatment with Kaftrio is able to significantly 
downregulate the ceramides in all the groups, although a trend of downregulation of this class of lipids 





Figure 50: Results of the targeted quantification of six ceramides in all the experimental groups. The dotted red line represents 
the average level of the control group. Box-and-whiskers plots represent the median value (inner bar), the first and third quartile 
(box), and the minimum and maximum value (outer bars). Data represent mean ± SEM, n = 5. *P < 0.05, **P < 0.01 compared 
with control, 1-way ANOVA test with Dunnett’st’s post hoc test. Figure adapted from Liessi N., Distinctive lipid signatures of 
bronchial epithelial cells associated with cystic fibrosis drugs, including Trikafta [149]. 
Ceramides are known to be involved in the induction of apoptosis [218]; moreover, it was demonstrated 
that the treatment with an inhibitor of ceramide biosynthesis (XM462) promoted cell survival in gastric 
carcinoma HCG27 cell line [219]. Given the known role of ceramides, the biological relevance of these 
results was further investigated through the evaluation of the response of the CFBE41o- cells to pro-
apoptotic stimuli after the treatment with Kaftrio (Paragraph 3.4.5). The hypothesis was that, by lowering 
the ceramide levels by pharmacological treatment, the cells should have shown a decrease in 
susceptibility to apoptosis.  
CFBE41o- cells expressing F508del-CFTR were then exposed to different concentrations (1–10 μM) of 
etoposide, a topoisomerase II inhibitor able to induce apoptosis in bronchial cells (Paragraph 3.4.5). The 
following day, the number of living cells was evaluated for each condition (Figure 51). The results showed 
that none of the pharmacological treatments that were investigated affects the number of living cells 
under resting condition. Nevertheless, when a pro-apoptotic stimulus (etoposide) is given, the number of 
viable cells decreases following a dose-dependent way. However, when etoposide is added to the cells in 
the presence of the Kaftrio treatment, the number of viable cells is consistently higher in comparison to 




Figure 51: CFBE41o- cells were treated for 24 hours with vehicle alone or with the indicated concentrations of etoposide to 
induce apoptosis, in the absence or presence of different CFTR modulators. Samples were then analyzed by automated high-
content imaging and analysis. (A) Representative images. Scale bar: 200 μm. (B) Quantification of the number of viable 
CFBE41o- cells per condition. Data represent mean ± SEM, n = 5. *P < 0.05, **P < 0.01 compared with respective control (DMSO-
treated) cells, 1-way ANOVA test with Dunnett’st’s post hoc test. . Figure adapted from Liessi N., Distinctive lipid signatures of 
bronchial epithelial cells associated with cystic fibrosis drugs, including Trikafta [149]. 
The results of this experiment show that, when cells undergo the pro-apoptotic stimuli, only the treatment 
with the triple combination of drugs has a protective effect, measured by the higher number of viable 
cells. On the contrary, cells treated with other CF drugs (either alone or in combination) showed a 
decrease in the number of viable cells after the pro-apoptotic stimulus. Taken together these results 
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suggest that the downregulation of the six major ceramides might have a protective role in cell response 
to pro-apoptotic stimuli.   
Beside the ceramides, a downregulation of the three major Lysophosphatidylcholines (LysoPCs) was also 
detected by the untargeted experiment.   
Despite their possible role as biomarkers for CF in some biofluids [219], their exact role in CF is not 
completely clear yet. LysoPCs are known not only to be secreted to attract macrophages [220] but also to 
be the precursors of molecules (phosphocholine and glycerophosphocholine) involved in the regulation 
of the membrane fluidity in mammalian cells [221].  
The targeted analysis of LysoPCs conducted (Paragraph 3.4.4) for this work shows that the decrease of 
this class of lipids is caused only by the treatment with the triple combination of drugs (Figure 52, Panel 
A).  
 
Figure 52: Targeted quantification of three LysoPCs in the CFBE41o- cells. (A) LysoPC levels in lysates following treatment with 
the triple combination (VX-661/ VX-445/VX-770) after 24 hours of incubation. The average level of the control group is 
represented by the dotted red line. §p < 0.05 compared with control, 1-way ANOVA test with Dunnett’st’s post hoc test. (B) 
LysoPC levels in the supernatants of the same CFBE41o- cells at 24 hours, following treatment with the triple combination. The 
average level in the medium at the beginning of the incubation is indicated by the dotted green line. Box-and-whiskers plot 
represent the median value (inner bar), the first and third quartile (box), and the minimum and maximum value (outer bars). 
Data represent mean ± SEM, n = 5. *P < 0.05 compared with control, 2-tailed t test. Figure taken from Liessi N., Distinctive lipid 
signatures of bronchial epithelial cells associated with cystic fibrosis drugs, including Trikafta [149]. 
These lipids were also measured in the supernatant of the cells, where their levels are higher if compared 
to the controls (Figure 52, Panel B). This suggested that the cells, when treated with Kaftrio, reduce the 
consumption of LysoPCs to produce PCs, which are downregulated together with the LysoPCs in the 




4.5 LOPIT-DC experiments 
4.5.1 Evaluation of the separation of the organelles through WB 
In the frame of this work, we also conducted a set of LOPIT-DC (Localization of Organelle Proteins by 
Isotopic Tagging – Differential Centrifugation, [87]) experiments at the University of Cambridge, in 
collaboration with Prof. Kathryn Lilley. The biological role and function of a protein is not only related to 
its level of expression and biochemical activity, but it is also related to where this activity is carried out 
within the cell. LOPIT-DC enables the proteome-scale exploration of the spatial distribution and 
localization of thousands of proteins within the cell, thanks to its ability to separate the different cell 
organelles by density ultracentrifugation and to label them with specific isotopically coded tags.  
Since CF is (also) a trafficking disease, we explored the idea that the LOPIT-DC protocol could be 
successfully applied to CF research and that this technology could highlight proteins changing their spatial 
localization in the cell, particularly after CFTR rescue induced by treatment with VX-809. The hypothesis 
is, again, that omics data helps understanding the alterations in the cell chemical space composition 
associated to successful CFTR rescue, thus generating knowledge and, hopefully, new pharmacological 
targets.   
During the optimization of LOPIT-DC workflow, Western blotting can help in getting information about 
the distribution of key organelle markers through the collected fractions (for information about the 
antibodies used, please refer to Paragraph 3.5.2). After the optimization steps, LOPIT-DC workflow was 
applied to three biological replicates of CFBE41o- cells after the treatment with VX-809 (1 µM for 24 hours) 
and their controls. To confirm the efficiency of the organelles separation, for each sample (6 in total, 3 
controls and 3 treated) Western-blotting were performed. The corresponding results of the WB are 
showed in Figure 53. 
 
Figure 53: Wester-Blot of Control replicate 1 of CFBE41o- cells after LOPIT-DC centrifugation steps. 
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This figure shows the profile of each organelle marker in all the fractions collected in the LOPIT-DC 
experiment. In the LOPIT-DC, several centrifugation steps are performed and a total of ten fractions are 
normally collected. LOPIT-DC relies on the evidence that proteins from the same subcellular compartment 
show the same abundance profile across the fractions collected by differential centrifugation. Western 
blotting is used to evaluate the efficiency in organelle separation, using organelle-specific marker proteins.  
To achieve a proper separation of the organelles, each organelle-specific marker protein must show a 
unique profile distribution along the ten fractions. For some organelles, the separation is clearly 
detectable. For example, from Figure 53 it is clear that mitochondria proteins are present only in the first 
two fractions.  
Nevertheless, even though for some organelle markers the separation is not as evident as for the 
mitochondria, their profile distribution is still unique and adequate to achieve the organelle separations. 
Indeed, ER marker profile is highly enriched in fraction 5 and even though the signal is present in many of 
the fractions its profile is still unique.  
From these results, it is clear that the organelles separation was achieved by applying the LOPIT-DC 
workflow. As positive control, the whole cells fraction (WC) is also blotted: as expected, a signal for each 
organelle is detected in the whole cells fraction since in this fraction all the organelles are present all 
together.  
4.5.2 PCA score plots 
With LC-MS/MS experiments, more than 5000 proteins were quantified in each sample. The exact 
numbers of the quantified proteins, after normalization and missing values removal, are summarized in 
Table 12.   








Table 12: Table summarizing the quantified proteins in each sample after the LC-MS/MS analysis. 
After applying the analytical workflow for the spatial proteomics data [181], six PCA score plot maps were 
built to evaluate the efficiency of the organelle separations in all the samples.  
The three replicates were combined together obtaining new maps (one for the controls and one for the 





Figure 54: PCA score plots of the combined replicates of each condition. Panel A shows the PCA score plot of the control sample 
and Panel B shows the plot for the combined treated samples. 
Each of these maps represents the final step of the LOPIT-DC analysis. Each dot represents a protein 
quantified in the sample and its position in the map is linked to its profile distribution along the fractions 
collected. Proteins with similar profiles are close in the PCA score plot, while proteins with very different 
profile distribution are distant in the map.  
The colored dots are the proteins used as markers for specific organelle (each color corresponds to an 
organelle), while the grey dots are proteins with unknown localization. From these maps, a clear 
clusterization of the organelles can be detected, thus indicating that an effective organelle separation was 
achieved for CFBE41o- cells. While some organelles do not appear perfectly separated over PC1 and PC2, 
PCA plot over other principal components, like PC3, indicates the separation is visible. As an example, 




Figure 55: PCA maps of Control, replicate 3 over different PCs. Percentage variance explained by each component is shown in 
parentheses. 
From Figure 55, the separation of nucleus (black dots) and the ribosome (purple dots) is visible over PC1 
and PC3, while the separation of Golgi apparatus (dark green dots) and ER (pink dots) is detected over PC2 
and PC4.  
4.5.3 Data statistics to detect movers  
In order to introduce data statistics of the three replicates per group in the LOPIT-DC spatial analysis, the 
SVM classification was performed using the 4368 proteins in common between the controls and the 
treated samples following a dedicated workflow for spatial proteomics data [181]. 










Organelle Controls Treated 
Cytosol 581 561 
ER 264 269 
Golgi 48 43 
Lysosome 34 34 
Mitochondria 197 197 
Nucleus 809 836 
Nucleus-chromatin 127 134 
Peroxisome 25 25 
PM 158 154 
Proteasome 49 48 
Ribosome 168 162 
Unknown 1908 1905 
 
Table 13: Summary of proteins having an organelle-specific localization after the SVM classification. 
Another statistical analysis was performed [89] to identify the movers, those proteins that change their 
localization after the treatment.  
4.5.4 The movers  
To detect proteins that changed their localization after the treatment with VX-809 (“movers”), TAGM (t-
augmented Gaussian mixture) statistical analysis was performed, following a well-established workflow 
[89]. From the TAGM analysis, 231 movers were identified. A score, directly proportional to the difference 
between the profiles of the controls and the treated samples, was calculated for each of these proteins.  
Interestingly, CFTR was not detected among the movers. Indeed, CFTR was detected in ER in both the 
control and the treated samples. This result is not surprising since F508del-CFTR resides mainly in the ER 
(as opposed to the wt-CFTR, which is more present at the PM) [34]. Moreover, these cells were created 
and selected to stably overexpress only F508del-CFTR, whose primary localization is the ER. LOPIT-DC, as 
several profiling spatial proteomics methods, detects only the main (or primary) localization of the 
proteins - the subcellular niche where the proteins are resident for most of their life cycle [222]. LOPIT-
DC workflow is not able to detect the relatively small amount of CFTR (less than 30%) known to be rescued 
by VX-809, and yet able to elicit a pharmacologically relevant effect on the CF condition [223], [148]. 
Among the proteins classified as movers, 6 CFTR interactors were detected. As shown in Table 14, the 
Bayes Factor associated to these proteins is quite low, suggesting that their subcellular localization is not 







Accession Protein names Gene Bayes Factor 
Q9Y385 
Ubiquitin-conjugating enzyme E2 J1 (EC 2.3.2.23) (E2 
ubiquitin-conjugating enzyme J1) (Non-canonical ubiquitin-
conjugating enzyme 1) (NCUBE-1) (Yeast ubiquitin-
conjugating enzyme UBC6 homolog E) (HsUBC6e) 
UBE2J1 95.83 
Q9UBV2 




Protein transport protein Sec61 subunit alpha isoform 1 
(cDNA FLJ59739, highly similar to Protein transport protein 
Sec61 subunit alpha isoform 1) 
SEC61A1 60.71 
O43520 
Phospholipid-transporting ATPase IC (EC 7.6.2.1) (ATPase 
class I type 8B member 1) (Familial intrahepatic cholestasis 
type 1) (P4-ATPase flippase complex alpha subunit ATP8B1) 
ATP8B1 44.23 
J3KPS0 
DnaJ (Hsp40) homolog, subfamily B, member 12, isoform 
CRA_c (DnaJ homolog subfamily B member 12) 
DNAJB12 42.15 
P17612 
cAMP-dependent protein kinase catalytic subunit alpha (PKA 
C-alpha) (EC 2.7.11.11) 
PRKACA 41.41 
Table 14: List of CFTR interactors among the proteins classified as movers after the treatment with the VX-809. 
Moreover, proteins involved in protein transport were detected among the movers and they are listed in 


















Accession Protein names Gene Bayes Factor 
P35914 Hydroxymethylglutaryl-CoA lyase, mitochondrial (HL) 
(HMG-CoA lyase) (EC 4.1.3.4) (3-hydroxy-3-
methylglutarate-CoA lyase) 
HMGCL 286.94 
A8MXV4 Nucleoside diphosphate-linked moiety X motif 19 (Nudix 
motif 19) (EC 3.6.1.-) 
NUDT19 145.55 
Q86WA8 Lon protease homolog 2, peroxisomal (EC 3.4.21.53) (Lon 
protease-like protein 2) (Lon protease 2) (Peroxisomal 
Lon protease) (pLon) 
LONP2 129.46 
P12235 ADP/ATP translocase 1 (ADP,ATP carrier protein 1) 
(ADP,ATP carrier protein, heart/skeletal muscle isoform 
T1) (Adenine nucleotide translocator 1) (ANT 1) (Solute 
carrier family 25 member 4) 
SLC25A4 90.87 
Q9NS69 Mitochondrial import receptor subunit TOM22 homolog 
(hTom22) (1C9-2) (Translocase of outer membrane 22 
kDa subunit homolog) 
TOMM22 86.07 
P12236 ADP/ATP translocase 3 (ADP,ATP carrier protein 3) 
(ADP,ATP carrier protein, isoform T2) (ANT 2) (Adenine 
nucleotide translocator 3) (ANT 3) (Solute carrier family 
25 member 6) [Cleaved into: ADP/ATP translocase 3, N-
terminally processed] 
SLC25A6 73.44 
C9JRZ6 MICOS complex subunit CHCHD3 57.18 
Q16595 Frataxin, mitochondrial (EC 1.16.3.1) (Friedreich ataxia 
protein) (Fxn) [Cleaved into: Frataxin intermediate form 
(i-FXN); Frataxin(56-210) (m56-FXN); Frataxin(78-210) (d-
FXN) (m78-FXN); Frataxin mature form (Frataxin(81-210)) 
(m81-FXN)] 
FXN 51.19 
B7Z2R7 Acyl-CoA-binding domain-containing protein 5 ACBD5 49.98 
Q3ZCQ8 Mitochondrial import inner membrane translocase 
subunit TIM50 
TIMM50 48.20 
O43808 Peroxisomal membrane protein PMP34 (34 kDa 
peroxisomal membrane protein) (Solute carrier family 25 
member 17) 
SLC25A17 44.72 
A0A0C4DGA2 Enoyl-CoA delta isomerase 2, mitochondrial (Testicular 
secretory protein Li 33) 
ECI2 44.68 
Q92968 Peroxisomal membrane protein PEX13 (Peroxin-13) PEX13 44.37 
Table 15: Proteins involved in protein transport among the movers detected by LOPIT-DC experiments. 
The full paper reporting the whole set of results for the application of LOPIT-DC to CFBE41o- cells is almost 









My research work deals with the use of advanced MS-based omics tools to further investigate the 
pathophysiology of cystic fibrosis and to highlight changes in the chemical space composition of CFBE41o- 
cells resulting from successful CFTR rescue maneuvers. The final aim of this effort is to generate data 
useful to uncover new biological mechanisms contributing to CF disease and, hopefully, to identify new 
potential targets for the pharmacological treatment of CF. In the present work, several MS-based omics 
techniques were applied to gain an insight into the molecular mechanisms associated with the rescue of 
the mutant CFTR at the plasma membrane.   
First, and in view of the subsequent experimental activities, a new tool for label-free proteomics workflow 
was developed and optimized, making this powerful MS-based protocol perfectly suitable for CF research. 
We deeply analyzed the proteome of both immortalized and primary bronchial epithelium cells following 
several fractionation strategies in order to identify proteins specifically expressed in bronchial epithelium 
cells. We added to the Pan human ion library – the most complete ion library available so far for human 
samples - assays to quantify CFTR and other proteins known to be involved in CF pathology.  
With this new resource in hand, a deep proteomic profiling of BE primary cells was performed, by 
comparing the proteomes of four CF patients with four non-CF subjects, used as controls. We aimed at 
demonstrating the suitability of our newly-developed ion library for CF research. Moreover, we wanted 
to study and monitor changes in protein expression induced by CF pathology in well-differentiated 
bronchial epithelial cells. Many proteins (and pathways) were found to be significantly dysregulated by 
the disease. Several of these proteins are known to be direct CFTR interactors or proteins involved in CFTR 
trafficking and degradation. This study led to the publication of my first paper as first author in 2018 in 
the Journal of Cystic Fibrosis [151].  
A similar approach to identify proteins with a differential expression in CF was performed both by Bini’s 
group in 2018 [112] and by Yate’s group in 2014 [224]: the proteome of CFBE41o- cells (expressing 
F508del-CFTR) was compared to that of 16HBE14o- cells (expressing wt-CFTR). Despite the use of different 
quantitative approaches and different nature of the samples, we found some proteins dysregulated in CF 
in common with these studies, such as the tubulin alpha-1B chain (TUBA1B) and the protein S100-A6. It is 
important to keep in mind that data obtained with immortalized cell lines may not be representative of 
the in-vivo phenotype. For this reason, the dysregulation of the proteins in common between these 
studies can suggest their potential crucial role in CF biology.   
Despite the limited number of subjects, we believe that our work represents an improvement in the 
investigation of primary cells derived from CF patients. The lack of CFTR among the quantified protein was 
somehow expected, given its low natural abundance in human bronchial epithelium cells. On the other 
hand, our newly-developed IL enables us to quantify CFTR in all the experiments conducted using 
CFBE41o- cells: this cell model was created for the purpose of over-expressing the mutant channel; 
therefore it comes as no surprise that we detected CFTR in these cells.  
The levels of F508del-CFTR were found to be significantly increased in association with the gene silencing 
of the four “primary targets” – proteins that, when silenced are known to trigger mutant CFTR rescue at 
the plasma membrane [148]. The significant increase in CFTR levels following genetic maneuvers is an 
expected result: the proteins whose expressions were inhibited are known (or supposed to) interfere with 




We used this approach to highlight proteins whose levels of expressions are altered in association with 
CFTR rescue. Our aim with this experiment was to gain a crucial understanding of how the cell reacts to 
F508del-CFTR rescue. Our strategy was to use siRNA to selectively silence four primary targets (known to 
trigger CFTR rescue) in order to detect the proteins and the pathways significantly altered by this genetic 
CFTR rescue. This approach allowed us to identify a list of putative new targets to be further investigated. 
We then used data mining strategies and tools to select molecules able to modulate these targets and we 
tested them on CFBE41o- cells to assess their effect on CFTR rescue. Some of these compounds indeed 
succeeded in inducing CFTR rescue. On the other hand, the only compound that we tested on bronchial 
epithelium cells so far failed to show the same effect on primary cells. Due to a set of unexpected delays, 
mainly related to the 2020 COVID-19 pandemic, further tests on the remaining compounds are still 
pending. In any case, as expected from the beginning of the project, further efforts are still needed to 
translate CFTR rescue from CFBE41o- to primary cells. Indeed, early validation of primary hits in a native 
cell model is a crucial step in CF drug development, due to the demonstrated influence of cell background 
on the pharmacological rescue of mutant CFTR, in particular for compounds acting as correctors of the 
maturation defect [225], [226].      
Beside the genetic rescue of CFTR obtained by siRNA, we also investigated the alterations associated with 
a pharmacological rescue. Although several recent studies were published to highlight the importance of 
membrane lipids in the physiology and trafficking of CFTR, an untargeted lipidomics profiling of bronchial 
epithelial cells was never performed. For this reason, we investigated how CF drugs alter the CFBE41o- 
lipidome. We hypothesized that the pharmacological rescue of mutant CFTR could be associated with 
changes in lipidome profile of CFBE41o- cells. 
In this work, the first untargeted lipidome profiling of CFBE41o- was conducted to study the effect of 
different pharmacological treatments on lipids. This study led a publication of a paper in the JCI Insight 
journal [149]. The results of this experiment demonstrated that each of the tested drugs triggers a 
characteristic change in the cell lipidome. We found that VX-770 is associated with a particular lipid 
signature, consisting in the decrease of 7 phosphatidylcholines and a ceramide. Moreover, we discovered 
that the treatment with Kaftrio induces a significant decrease of 6 ceramides. This effect is also associated 
with an increased resistance of treated CFBE41o- to pro-apoptotic stimuli. These findings represent a first 
step for future research to define the role of lipids, and sphingolipids in particular, in mutant CFTR rescue. 
Indeed, in the last few years, the crucial role of membrane lipids in CF was investigated. In particular, 
cholesterol influences the fluidity of the plasma membrane, as it forms lipid clusters and rafts together 
with sphingomyelin [227]. This topic is important in CF research as in murine tracheal epithelial cells CFTR 
was found to colocalize with these lipid rafts [228]; the presence of CFTR in lipid rafts is essential during 
P. aeruginosa infection [229]. Given that the surrounding lipid environment can affect CFTR activity, 
studying the imbalances of lipids in people with CF can shed light on their role in CF biology. Moreover, 
the modulators of CFTR activity can act at their full potential if CFTR is in a proper lipid environment. For 
this reason, we think that our untargeted profiling of changes in lipids associated with different 
pharmacological treatments can be of help to future research in this field.   
Finally, in the last part of my work, the LOPIT-DC workflow was applied to the CFBE41o- cells. LOPIT-DC is 
the current state-of-the-art tool to simultaneous investigate the subcellular localization of the proteins 
from complex biological mixtures in a single experiment. 
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With the help of Prof. Lilley’s group at the University of Cambridge, LOPIT-DC workflow was optimized to 
obtain the first subcellular protein localization map of CFBE41o- cells. We then investigated if a 
pharmacological F508del-CFTR rescue (obtained with the corrector VX-809) alters the subcellular 
localization of proteins in CFBE41o- cells. We found that the treatment with the corrector VX-809 is 
associated with changes in subcellular localization of more than 200 proteins, defined as “movers”. The 
detected movers could be involved in the functional rescue of the mutant CFTR or related to CFTR activity 
and trafficking. We believe that the identification of these “movers” can help in further understanding of 
the CF pathophysiological mechanisms and perhaps help the quest for new pharmacological targets.  
Many different versions of LOPIT protocol have been published [78]–[83], [87] but this method was often 
applied to a “static” situation: the subcellular protein localization was investigated using only a single 
condition. For the first time, with our experiment, LOPIT-DC was applied to CF research.  Moreover, we 
studied a “dynamic situation”, comparing two different conditions in order to detect those proteins that 
changed their subcellular localization in association with the pharmacological rescue of the mutant CFTR.   
Since CF is (also) a trafficking disease, we explored the idea that the LOPIT-DC protocol could be 
successfully applied to CF research and that this technology could highlight proteins changing their spatial 
localization in the cell, particularly after CFTR rescue induced by treatment with VX-809. The hypothesis 
is, again, that omics data helps understanding the alterations in the cell chemical space composition 
associated to successful CFTR rescue, thus generating knowledge and, hopefully, new pharmacological 
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